WO2021029318A1 - 免疫チェックポイント阻害剤、免疫チェックポイント関連疾患の治療剤、免疫抑制剤、抗フィブロネクチン抗体又はその誘導体、フィブロネクチンアナログ、フィブロネクチンまたはその部分タンパク質を検出するためのキット、及びフィブロネクチンまたはその部分タンパク質を検出する方法 - Google Patents
免疫チェックポイント阻害剤、免疫チェックポイント関連疾患の治療剤、免疫抑制剤、抗フィブロネクチン抗体又はその誘導体、フィブロネクチンアナログ、フィブロネクチンまたはその部分タンパク質を検出するためのキット、及びフィブロネクチンまたはその部分タンパク質を検出する方法 Download PDFInfo
- Publication number
- WO2021029318A1 WO2021029318A1 PCT/JP2020/030175 JP2020030175W WO2021029318A1 WO 2021029318 A1 WO2021029318 A1 WO 2021029318A1 JP 2020030175 W JP2020030175 W JP 2020030175W WO 2021029318 A1 WO2021029318 A1 WO 2021029318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibronectin
- amino acid
- acid sequence
- antibody
- lilrb4
- Prior art date
Links
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 193
- 102000016359 Fibronectins Human genes 0.000 title claims abstract description 193
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 37
- 201000010099 disease Diseases 0.000 title claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 35
- 102000037982 Immune checkpoint proteins Human genes 0.000 title claims abstract description 33
- 108091008036 Immune checkpoint proteins Proteins 0.000 title claims abstract description 33
- 230000036961 partial effect Effects 0.000 title claims abstract description 29
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 27
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 27
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 27
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 27
- 239000003018 immunosuppressive agent Substances 0.000 title claims abstract description 20
- 229960003444 immunosuppressant agent Drugs 0.000 title claims abstract description 14
- 230000001861 immunosuppressant effect Effects 0.000 title claims abstract description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 50
- 239000000126 substance Substances 0.000 claims abstract description 37
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims abstract description 27
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims abstract description 27
- 239000012472 biological sample Substances 0.000 claims abstract description 10
- 230000027455 binding Effects 0.000 claims description 94
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 206010027476 Metastases Diseases 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 16
- 230000009401 metastasis Effects 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 229940027941 immunoglobulin g Drugs 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 109
- 241000699670 Mus sp. Species 0.000 description 69
- 241000699666 Mus <mouse, genus> Species 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 58
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 55
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 55
- 210000001744 T-lymphocyte Anatomy 0.000 description 48
- 230000002950 deficient Effects 0.000 description 38
- 239000012634 fragment Substances 0.000 description 38
- 241000282414 Homo sapiens Species 0.000 description 29
- 108020003175 receptors Proteins 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 29
- 238000010186 staining Methods 0.000 description 28
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 24
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 24
- 210000002997 osteoclast Anatomy 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 210000002798 bone marrow cell Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 229960002897 heparin Drugs 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 230000001394 metastastic effect Effects 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 229940126546 immune checkpoint molecule Drugs 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000012575 bio-layer interferometry Methods 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 102000046949 human MSC Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 101100128416 Homo sapiens LILRB4 gene Proteins 0.000 description 4
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 102000056823 human LILRB4 Human genes 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001204 Hashimoto Disease Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 101100025201 Mus musculus Msc gene Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000014128 RANK Ligand Human genes 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 108700010039 chimeric receptor Proteins 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 102000003908 Cathepsin D Human genes 0.000 description 2
- 108090000258 Cathepsin D Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 241000699679 Cricetulus migratorius Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000984206 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 6 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100025553 Leukocyte immunoglobulin-like receptor subfamily A member 6 Human genes 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101001027130 Mus musculus Fibronectin Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010069034 Tubulointerstitial nephritis and uveitis syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- -1 vaseline Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Definitions
- the present invention relates to immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, immunosuppressants, anti-fibronectin antibodies or derivatives thereof, fibronectin analogs, kits for detecting fibronectin or partial proteins thereof, and fibronectin or parts thereof. It relates to a method for detecting a protein.
- the present application claims priority based on Japanese Patent Application No. 2019-148423 filed in Japan on August 13, 2019, the contents of which are incorporated herein by reference.
- An immune checkpoint inhibitor is an immune checkpoint molecule that suppresses the immune response to itself and binds to an immune checkpoint molecule or its ligand that suppresses an excessive immune response, thereby inhibiting the transmission of immunosuppressive signals. It is a drug that releases the suppression of T cell activation by checkpoint molecules.
- LILRB4 Leukocyte Ig-like receptor B4, hereinafter also referred to as B4
- B4 an immunosuppressive receptor for an unknown ligand. It has been found that an inflammatory disease can be determined (Patent Document 1).
- Non-Patent Documents 1 to 3 Recently, CD166, ApoE, Angptls and the like have been reported as ligands for LILRB4 (Non-Patent Documents 1 to 3). However, the proof that these are physiological ligands is not sufficient.
- Fibronectin (hereinafter, also referred to as FN) is an extracellular matrix (hereinafter, also referred to as ECM), a glycoprotein of about 259 kDa present on the cell surface and in body fluids. Fibronectin is divided into 6 regions (domains) by treatment with the proteolytic enzyme thermolysin. These are based on their specific molecular binding ability. Fibrin / heparin binding region (Fibrin / Heparin binding-FN), 2. Collagen binding-FN, 3. Heparin binding region (Heparin binding-FN), 4. 4. Cell / integrin binding region (cell / integrin-binding-domine (CBD) -FN), 5. Second heparin binding region (second Heparin binding-FN), 6.
- ECM extracellular matrix
- thermolysin a glycoprotein of about 259 kDa present on the cell surface and in body fluids. Fibronectin is divided into 6 regions (domains) by treatment with the proteolytic enzyme thermolysin. These
- FN is composed of a plurality of domains having different binding abilities to physiological molecules. So far, in some autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), fluctuations in FN concentration in plasma and body fluid (for example, joint fluid) have been observed. , Domain analysis for evaluating FN fragmentation using a monoclonal antibody has been reported to be useful for disease diagnosis or severity evaluation (Non-Patent Documents 4 to 6).
- the Fibrin / Heparin binding-FN concentration was 24 ⁇ 12 ⁇ g / ml (p ⁇ 0.003) for SLE and 36 ⁇ 22 ⁇ g / ml (p ⁇ 0) for RA in comparison with healthy subjects (61 ⁇ 18 ⁇ g / ml). It is 0.0002) and is expected to be used for diagnosis.
- FN promotes the metastatic ability and infiltration ability of lung cancer cell lines (Non-Patent Document 7).
- Non-Patent Document 7 Non-Patent Document 7
- the present invention relates to immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, immunosuppressants, anti-fibronectin antibodies or derivatives thereof, fibronectin analogs, kits for detecting fibronectin or partial proteins thereof, and fibronectin or parts thereof. It is an object of the present invention to provide a method for detecting a protein.
- the present inventors have found that the physiological ligand of LILRB4 is fibronectin, which is one of the major constituent proteins of ECM, identifies the target sequence of LILRB4 in fibronectin, and inhibits the binding between this target sequence and fibronectin.
- the present invention has been completed by finding that the substance is useful as an immune checkpoint inhibitor, a therapeutic agent for immune checkpoint-related diseases, and an immunosuppressive agent.
- the present invention includes the following aspects. [1] An immune checkpoint inhibitor containing a substance that inhibits the binding of fibronectin to the immunosuppressive receptor LILRB4 as an active ingredient.
- the substance that inhibits the binding of fibronectin to the immunosuppressive receptor LILRB4 is an anti-fibronectin antibody or a derivative thereof, an anti-immunosuppressive receptor LILRB4 antibody or a derivative thereof, or a fibronectin analog, [1] or The immune checkpoint inhibitor according to [2].
- fibronectin analog is a peptide according to any one of the following (a) to (c).
- A A peptide containing the amino acid sequence represented by SEQ ID NO: 1.
- B In the amino acid sequence represented by SEQ ID NO: 1, one to several amino acids contain an amino acid sequence deleted, inserted, substituted or added, and with respect to the fibronectin binding site of the immunosuppressive receptor LILRB4.
- fibronectin A therapeutic agent for an immune checkpoint-related disease containing a substance that inhibits the binding of the immunosuppressive receptor LILRB4 as an active ingredient. [7] The therapeutic agent according to [6], wherein the fibronectin binds to the immunosuppressive receptor LILRB4 via the amino acid sequence represented by SEQ ID NO: 1 in the fibronectin.
- the substance that inhibits the binding between fibronectin and the immunosuppressive receptor LILRB4 is an anti-fibronectin antibody or a derivative thereof, an anti-immunosuppressive receptor LILRB4 antibody or a derivative thereof, or a fibronectin analog, [6] or The therapeutic agent according to [7].
- the therapeutic agent according to [8], wherein the anti-fibronectin antibody or a derivative thereof binds to the amino acid sequence represented by SEQ ID NO: 1 in fibronectin.
- the therapeutic agent according to [8], wherein the fibronectin analog is a peptide according to any one of the following (a) to (c). (A) A peptide containing the amino acid sequence represented by SEQ ID NO: 1.
- the therapeutic agent according to any one of [6] to [10], wherein the immune checkpoint-related disease is selected from the group consisting of autoimmune diseases, cancers, inflammatory diseases, and allergic diseases.
- a therapeutic agent for an immune checkpoint-related disease containing a substance that activates the immunosuppressive receptor LILRB4 as an active ingredient.
- the substance that activates the immunosuppressive receptor LILRB4 is an anti-fibronectin antibody or a derivative thereof, an anti-immunosuppressive receptor LILRB4 antibody or a derivative thereof, or a fibronectin or a fibronectin analog, according to [13].
- Therapeutic agent. [15] The therapeutic agent according to [14], wherein the fibronectin analog is a peptide according to any one of the following (a) to (c).
- A A peptide containing the amino acid sequence represented by SEQ ID NO: 1.
- B In the amino acid sequence represented by SEQ ID NO: 1, one to several amino acids contain an amino acid sequence deleted, inserted, substituted or added, and with respect to the fibronectin binding site of the immunosuppressive receptor LILRB4. Peptides with binding ability,
- C A peptide containing an amino acid sequence having 80% or more identity in the amino acid sequence represented by SEQ ID NO: 1 and having a binding ability to the fibronectin binding site of the immunosuppressive receptor LILRB4 [16].
- the therapeutic agent according to any one of [13] to [15], wherein the immune checkpoint-related disease is a bone disease.
- the substance that activates the immunosuppressive receptor LILRB4 is an anti-fibronectin antibody or a derivative thereof, an anti-immunosuppressive receptor LILRB4 antibody or a derivative thereof, or a fibronectin or a fibronectin analog, according to [17].
- Immunosuppressant. [19] The immunosuppressant according to [18], wherein the fibronectin analog is a peptide according to any one of the following (a) to (c). (A) A peptide containing the amino acid sequence represented by SEQ ID NO: 1.
- a fibronectin analog in which any one of the following peptides (a) to (c) and the Fc region of immunoglobulin G are fused.
- A A peptide containing the amino acid sequence represented by SEQ ID NO: 1.
- B In the amino acid sequence represented by SEQ ID NO: 1, one to several amino acids contain an amino acid sequence deleted, inserted, substituted or added, and with respect to the fibronectin binding site of the immunosuppressive receptor LILRB4.
- Peptides with binding ability (C) In the amino acid sequence represented by SEQ ID NO: 1, a peptide containing an amino acid sequence having 80% or more identity and having a binding ability to the fibronectin binding site of the immunosuppressive receptor LILRB4 [22] [ 20] A kit for detecting fibronectin or a partial protein thereof, which comprises the anti-fibronectin antibody or derivative thereof and contains the amino acid sequence represented by SEQ ID NO: 1 contained in a biological sample. [23] A method for detecting fibronectin or a partial protein thereof in a biological sample using the kit according to [22].
- immune checkpoint inhibitors therapeutic agents for immune checkpoint-related diseases, immunosuppressants, anti-fibronectin antibodies or derivatives thereof, fibronectin analogs, kits for detecting fibronectin or partial proteins thereof, and fibronectin or A method for detecting the partial protein can be provided.
- B4 left, PD-1 (center), Tim-3 (right) in activation stimulation of mouse wild-type CD8-positive T cells (upper) and B4-deficient CD8-positive T cells (lower) with anti-CD3 antibody / anti-CD28 antibody ) Is analyzed over time (day 0-3) by flow cytometry.
- the vertical axis shows the proportion of cells when the peak value of the histogram is 100%, and the horizontal axis shows the histogram of each measurement day shown by the fluorescence intensity (protein expression intensity).
- the solid line shows the result of staining with each antigen-specific antibody, and the gray without solid line shows the result of staining with the isotype control antibody.
- B4 left), PD-1 (center), Tim-3 (right) in activation stimulation of mouse wild-type CD4-positive T cells (upper) and B4-deficient CD4-positive T cells (lower) with anti-CD3 antibody / anti-CD28 antibody ) Is analyzed over time (day 0-3) by flow cytometry.
- the vertical axis shows the proportion of cells when the peak value of the histogram is 100%, and the horizontal axis shows the histogram of each measurement day shown by the fluorescence intensity (protein expression intensity).
- the solid line shows the result of staining with each antigen-specific antibody, and the gray without solid line shows the result of staining with the isotype control antibody.
- the results of the analysis are shown in (eyes).
- the vertical axis represents the expression intensity of PD-1
- the horizontal axis represents the expression intensity of B4
- the lower left area separated by a cross is PD-1 negative B4 negative
- the upper left area is PD-1 alone positive
- the upper right area is PD.
- the -1 positive B4 positive and the lower right area represent PD-1 negative B4 positive, respectively.
- the results of evaluating the FN-B4 binding inhibitory effect of an anti-FN30 monoclonal antibody by the proportion of GFP-expressing cells of B4-GFP reporter cells in co-culture of human MSC and B4-GFP reporter cells are shown.
- the vertical axis of the plot shows the cell size
- the horizontal axis shows the fluorescence intensity of GFP
- the numerical values in the plot show the percentage (%) of GFP-positive cells (in the frame).
- the bar graph shows the percentage of GFP-positive cells when treated with each antibody.
- the results of staining mouse bone marrow-derived mesenchymal stem cells and human bone marrow-derived mesenchymal stem cells with an anti-FN30 monoclonal antibody and analyzing them with a flow cytometer are shown.
- the solid line shows the result of staining with the anti-FN30 monoclonal antibody, and the gray without the solid line shows the result of staining with the isotype control antibody.
- Anti-FN30 monoclonal antibody No. 5 is used to stain a mouse cancer cell line (upper row) and a human cancer cell line (lower row), and the results of analysis with a flow cytometer are shown.
- the solid line shows the result of staining with the anti-FN30 monoclonal antibody, and the gray without the solid line shows the result of staining with the isotype control antibody.
- the result of analyzing the expression of is with a flow cytometer is shown.
- the vertical axis represents the expression intensity of PD-1
- the horizontal axis represents the expression intensity of B4
- the lower left area separated by a cross is PD-1 negative B4 negative
- the upper left area is PD-1 alone positive
- the upper right area is PD.
- the -1 positive B4 positive and the lower right area represent PD-1 negative B4 positive, respectively.
- B4 and PD-1 for CD4-positive T cells infiltrating into tumors formed by ingesting B16F10 cell lines (upper two) and 3LL cell lines (lower, three) into wild-type mice The result of analyzing the expression of is with a flow cytometer is shown.
- the vertical axis represents the expression intensity of PD-1
- the horizontal axis represents the expression intensity of B4
- the lower left area separated by a cross is PD-1 negative B4 negative
- the upper left area is PD-1 alone positive
- the upper right area is PD.
- the -1 positive B4 positive and the lower right area represent PD-1 negative B4 positive, respectively.
- the results of protein detection by Western blotting using an anti-fibronectin antibody in a human plasma sample are shown.
- the upper row shows the fibronectin concentration [A ( ⁇ g / ml)] detected by the anti-FN30 monoclonal antibody, and the lower row shows the fibronectin concentration [B ( ⁇ g / ml)] detected by the anti-FN44 antibody.
- a boxplot showing the first, second, and third quartiles and the maximum and minimum values of the full-length fibronectin molecule and the concentration of the fibronectin 24 kDa fragment in healthy human plasma using an anti-FN monoclonal antibody is shown. .. The left shows the full-length molecular concentration of fibronectin, and the right shows the concentration of the fibronectin 24 kDa fragment.
- mice The results of intraperitoneal administration of control IgG or FN30-Fc to BXSB / Yaa mice and measurement of anti-dsDNA IgG level in serum are shown.
- results of intraperitoneal administration of control IgG or anti-gp49B monoclonal antibody H1.1 to BXSB / Yaa mice and measurement of anti-dsDNA IgG level in serum are shown.
- results of H & E staining of the lung surface 30 days after injecting Lewis lung carcinoma cells (LLC) into wild-type (WT) B6 mice and gp49B-deficient mice through the tail vein are shown.
- WT indicates the result of wild-type mouse
- gp49B ⁇ / ⁇ indicates the result of gp49B deficient mouse.
- Lewis lungg carcinoma cells are injected from the tail vein into wild-type (WT) B6 mice and gp49B-deficient mice, and the quantitative results of the number of metastatic lesions in the lung after 30 days are shown.
- the results of H & E staining of the liver 30 days after injection of Lewis lung carcinoma cells (LLC) into wild-type (WT) B6 mice and gp49B-deficient mice from the tail vein are shown.
- WT indicates the result of wild-type mouse
- gp49B ⁇ / ⁇ indicates the result of gp49B deficient mouse.
- Lewis lungg carcinoma cells are injected from the tail vein into wild-type (WT) B6 mice and gp49B-deficient mice, and the quantification results of the number of metastatic lesions in the liver after 30 days are shown.
- the results of H & E staining of the lung surface after 20 days by injecting mouse melanoma cells B16F10 from the tail vein into wild-type (WT) B6 mice and gp49B-deficient mice are shown.
- WT indicates a wild-type mouse
- gp49B ⁇ / ⁇ indicates a gp49B-deficient mouse.
- the results of H & E staining of the liver after 20 days by injecting mouse melanoma cells B16F10 into wild-type (WT) B6 mice and gp49B-deficient mice through the tail vein are shown.
- WT indicates a wild-type mouse
- gp49B ⁇ / ⁇ indicates a gp49B-deficient mouse.
- the results of adoption of wild-type mouse bone marrow cells or gp49B-deficient mouse bone marrow cells are shown.
- the left shows the results of H & E staining of the lung (upper) and liver (lower), and the right shows the number of metastases in the lung (upper) and liver (lower).
- WT-R indicates a wild-type mouse
- gp49B ⁇ / ⁇ ⁇ R indicates a gp49B-deficient mouse.
- control isotype IgG antibody, anti-PD-1 monoclonal antibody, anti-gp49B monoclonal antibody, or combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody It is a figure which showed the metastatic state of the lung and the liver of the mouse which developed the B16F10 tumor by administration.
- the upper row shows tumor nodules in the lung, and the lower row shows H & E stained images of the liver.
- control isotype IgG antibody, anti-PD-1 monoclonal antibody, anti-gp49B monoclonal antibody, or combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody It is a graph comparing the number of tumor nodules in the lungs in each antibody-treated group.
- control isotype IgG antibody, anti-PD-1 monoclonal antibody, anti-gp49B monoclonal antibody, or combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody It is a graph which compared the number of B16F10 metastasis to the liver in each antibody treatment group.
- the results of induction of differentiation of bone marrow cells into osteoclasts by addition of 6 are shown.
- the photograph shows a TRAP-stained image of osteoclasts, and the graph shows the differentiation induction rate by each antibody addition.
- Mock shows the case where no antibody is added.
- the TRAP stained image of osteoclasts when the anti-LILRB4 monoclonal antibody ZM4.1 (right figure) or mouse IgG1 ⁇ (left figure) is added is shown.
- the results of inducing osteoclast differentiation from bone marrow cells of wild-type B6 mice or gp49B-deficient mice are shown.
- the left photo shows osteoclasts differentiated from bone marrow cells of wild-type B6 mice, and the right photo shows TRAP-stained images of osteoclasts differentiated from bone marrow cells of gp49B-deficient mice.
- the graph shows the differentiation induction rate when osteoclasts are induced to differentiate from bone marrow cells of wild-type B6 mice and bone marrow cells of gp49B-deficient mice, respectively.
- WT indicates wild-type B6 mice
- gp49B ⁇ / ⁇ and KO indicate gp49B deficient mice.
- a TRAP-stained image of osteoclasts in the femur of wild-type B6 mice and gp49B-deficient mice is shown.
- the left figure shows a TRAP-stained image of osteoclasts of a wild-type B6 mouse and the right figure shows a gp49B-deficient mouse.
- the immune checkpoint inhibitor of the present invention contains a substance that inhibits the binding of fibronectin to the immunosuppressive receptor LILRB4 as an active ingredient.
- Fibronectin can bind to LILRB4 via the amino acid sequence represented by SEQ ID NO: 1 in the fibronectin. That is, the amino acid sequence represented by SEQ ID NO: 1 is the target sequence in fibronectin of LILRB4.
- the substance that inhibits the binding between fibronectin and LILRB4 is not particularly limited as long as it is a substance having an activity that inhibits the binding between fibronectin and LILRB4, but is an anti-fibronectin antibody or its derivative, an anti-LIRB4 antibody or its derivative, and fibronectin. Examples include analog.
- the anti-fibronectin antibody may be either a monoclonal antibody or a polyclonal antibody as long as it is an antibody that reacts with fibronectin, but a monoclonal antibody is preferably used.
- the antibody can be prepared by a well-known method. For example, mice, rats, hamsters, rabbits, goats, sheep, chickens and the like are used as immunized animals for the production of polyclonal antibodies.
- Antiserum can be obtained from serum after the antigen is administered subcutaneously, intradermally, peritoneally or the like in an animal once or multiple times. When a protein or peptide is used as an antigen, immunization of a mixture with a replacement fluid having an immunostimulatory effect is more preferable.
- monoclonal antibodies for the production of monoclonal antibodies, known methods for producing monoclonal antibodies, such as Kamei Nagamune and Hiroshi Terada, “Monclonal Antibody” Hirokawa Shoten (1990), and Jame W. It can be produced according to Golding, "Monoclonal Antibody", 3rd edition, Academic Press, 1996. Monoclonal antibodies can also be prepared by the DNA immunization method, such as Nature 1992 Mar12; 356 152-154 and J. Mol. It can be produced with reference to Immunol Methods Mar 1; 249 147-154.
- fibronectin or a partial fragment (peptide) thereof, or a vector incorporating a cDNA encoding fibronectin or a partial fragment thereof can be used.
- a peptide containing the amino acid sequence represented by SEQ ID NO: 1 which is the target sequence of LILRB4 in fibronectin.
- a fibronectin vector which is a construct containing a gene encoding a peptide containing the amino acid sequence represented by SEQ ID NO: 1, can be used as an optimal immune antigen gene.
- the DNA immunization method uses any of a variety of gene transfer methods (eg, intramuscular injection, electroporation, gene gun, etc.) into an immunized animal, either alone or in combination with the above gene constructs. It can be carried out by injecting it subcutaneously into a rat or the like and incorporating it into cells.
- gene transfer methods eg, intramuscular injection, electroporation, gene gun, etc.
- the anti-fibronectin monoclonal antibody can be produced by a method of culturing a hybridoma prepared according to a conventional method and separating it from the culture supernatant, or a method of administering the hybridoma to a mammal compatible with the hybridoma and collecting it as ascites.
- the anti-fibronectin monoclonal antibody can also be produced by using a known gene recombination technique. Specifically, the monoclonal antibody produced by the hybridoma produced above and the gene encoding the antibody are cloned, a vector containing the gene is prepared, and this is introduced into a host cell to transform it.
- It can be prepared by obtaining a cell expressing a fibronectin antibody and culturing the cell.
- the cells, vector type, cell type, culture conditions, etc. used for this preparation are within the technical scope of those skilled in the art, and appropriate conditions can be set as appropriate.
- the antibody can be used after purifying it as needed.
- Examples of the method for purifying and isolating the antibody include conventionally known methods such as salting out such as ammonium sulfate precipitation method, gel filtration method such as Sephadex, ion exchange chromatography method, and affinity purification method using a protein A column. Be done.
- the derivative of the anti-fibronectin antibody examples include a fusion protein or fusion containing the anti-fibronectin antibody F (ab') 2 , F (ab) 2 , Fab', Fab, Fv, scFv, variants thereof, and an antibody moiety thereof. Peptides and the like can be mentioned.
- the derivative of the anti-fibronectin antibody can be produced according to a known method for producing an antibody derivative.
- the anti-fibronectin antibody or its derivative binds to the amino acid sequence represented by SEQ ID NO: 1 in fibronectin or a partial sequence thereof.
- the anti-fibronectin antibody or a derivative thereof inhibits the binding between fibronectin and LILRB4 by binding to the amino acid sequence represented by SEQ ID NO: 1 in fibronectin or a partial sequence thereof. Can be done.
- the anti-LILRB4 antibody either a monoclonal antibody or a polyclonal antibody may be used as long as it is an antibody that binds to LILRB4, but a monoclonal antibody is preferably used.
- the anti-LIRB4 antibody can be prepared by the same method as the anti-fibronectin antibody.
- the antigen used for producing the anti-LILRB4 antibody a vector incorporating a LILRB4 protein, a partial fragment (peptide) thereof, or a cDNA encoding the LILRB4 protein can be used.
- the full-length LILRB4 vector which is a structure containing the human LILRB4 full-length gene, is the optimal immune antigen gene, but in addition, a part of the LILRB4 sequence is inserted.
- the construct can also be used as an immune antigen gene.
- the region of LILRB4 (fibronectin binding site) in which the amino acid sequence represented by SEQ ID NO: 1, which is the target sequence of LILRB4 in fibronectin, binds to LILRB4 is preferable.
- the DNA immunization method uses any of a variety of gene transfer methods (eg, intramuscular injection, electroporation, gene gun, etc.) into an immunized animal, either alone or in combination with the above gene constructs. It can be carried out by injecting it subcutaneously into a rat or the like and incorporating it into cells.
- Purification of the anti-LIRB4 antibody can be performed by the same method as that of the anti-fibronectin antibody.
- the derivative of the anti-LILRB4 antibody include a fusion protein containing F (ab') 2 , F (ab) 2 , Fab', Fab, Fv, scFv, variants thereof, and an antibody portion of the anti-LILRB4 antibody. Examples include fusion peptides.
- the anti-LILRB4 antibody or a derivative thereof can inhibit fibronectin from binding to LILRB4 via the amino acid sequence represented by SEQ ID NO: 1 in fibronectin.
- Inhibition of the binding of fibronectin to LILRB4 can be performed by evaluating the inhibition of the binding of fibronectin to cells expressing LILRB4.
- the cells expressing LILRB4 are not particularly limited as long as they are cells expressing LILRB4, but for example, spleen cells, peripheral blood leukocytes, bone mast cells, or B cells isolated from them, traits. Examples thereof include cells, monocytes / macrophages, dendritic cells, eosinophils, eosinophils, neutrophils, mast cells, activated T cells and the like.
- LILRB4 The nucleotide sequence and amino acid sequence of LILRB4 can be known from the database provided by the National Center for Biotechnology Information (NCBI).
- NCBI National Center for Biotechnology Information
- LILRB4 for example, Entrez GeneID is 11006 (as of June 17, 2019)
- RefSeq ProteinID is NP_001265355.2, NP_0012653556.2, NP_001265357.2, NP_001265358. (Equivalent to ⁇ 5).
- Examples of the mouse (Mus musculus) LILRB4 include GeneID 14728 (as of June 24, 2016) and NP_030560.1.
- LILRB4 As the rat (Rattus norvegicus) LILRB4, the GeneID is 292594 (as of April 18, 2019). , RefSeq ProteinID is NP_001013916, and it is known that other animals also have LILRB4. Not limited to the above LILRB4, other LILRB4s are also included in the LILRB4 in the present invention.
- the nucleotide sequence and amino acid sequence of fibronectin can be obtained from the database provided by the National Center for Biotechnology Information (NCBI).
- NCBI National Center for Biotechnology Information
- Entrez GeneID is 2335
- RefSeq ProteinID is NP_997647, NP_001352447, XP_005246463 and the like.
- GeneID is 14268
- rat Rostus norvegicus
- GeneID is 25661
- RefSeq ProteinID is NP_062016
- other animals are also known to have fibronectin. .. Not limited to the above fibronectin, other fibronectins are also included in the fibronectin in the present invention.
- Fibronectin binds to LILRB4 present on the cell surface of plasma cells, T cells, macrophages, etc. via the amino acid sequence represented by SEQ ID NO: 1 in the fibronectin, and activates an immune checkpoint molecule.
- LILRB4 expresses an immunosuppressive function by binding to fibronectin via the amino acid sequence represented by SEQ ID NO: 1 in fibronectin.
- the fibronectin analog includes any fibronectin analog as long as it has an action of inhibiting the binding between fibronectin and LILRB4, and for example, any one of the following (a) to (c).
- the identity of the amino acid sequence is 80% or more, preferably 85% or more, more preferably 90% or more, further preferably 95% or more, still more preferably 98% or more.
- the number of deletions, substitutions or additions of the above amino acid sequence is preferably 1 to 5, more preferably 1 to 4, further preferably 1 to 3, and even more preferably 1 to 2.
- Amino acid sequence identity can be determined by BLAST search provided on the GenBank database.
- the fibronectin analog may be a fibronectin analog in which any one of the peptides (a) to (c) and the Fc region of immunoglobulin G are fused.
- the fibronectin analog can be produced by a known method, for example, a gene recombination technique.
- the immune checkpoint inhibitor of the present invention contains a substance that inhibits the binding between fibronectin and LILRB4 as an active ingredient, and may further contain a pharmaceutically acceptable carrier or additive.
- carriers and additives include pharmaceutically acceptable organic solvents such as water, saline, phosphate buffer, dextrose, glycerol, ethanol, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose, etc.
- pharmaceutically acceptable organic solvents such as water, saline, phosphate buffer, dextrose, glycerol, ethanol, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose, etc.
- Sodium polyacrylate sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, vaseline, paraffin, stearyl alcohol , Steeric acid, human serum albumin, mannitol, sorbitol, lactose, surfactants and the like, but are not limited thereto.
- the immune checkpoint inhibitor of the present invention can be in various forms, such as liquids (eg, injections), dispersants, suspensions, tablets, pills, powders, suppositories and the like.
- a preferred embodiment is an injection, which is preferably administered parenterally (eg, intravenously, transdermally, intraperitoneally, intramuscularly).
- the immune checkpoint inhibitor of the present invention can be used as a therapeutic agent for immune checkpoint-related diseases.
- the dose of the immune checkpoint inhibitor of the present invention is, for example, 0.025 to 50 mg / kg, preferably 0.1 to 50 mg / kg, more preferably 0.1 to 25 mg / kg, still more preferably 0. It can be 1-10 mg / kg or 0.1-3 mg / kg, but is not limited to this.
- the therapeutic agent for immune checkpoint-related diseases of the present invention contains a substance that inhibits the binding between fibronectin and LILRB4 as an active ingredient.
- the substance that inhibits the binding between fibronectin and LILRB4 is not particularly limited as long as it is a substance having an activity that inhibits the binding between fibronectin and LILRB4, but is an anti-fibronectin antibody or its derivative, an anti-LIRB4 antibody or its derivative, and fibronectin. Examples include analog. Examples of the anti-fibronectin antibody or its derivative, the anti-LILRB4 antibody or its derivative, and the fibronectin analog include those described above.
- the immune checkpoint-related disease is not particularly limited as long as it is a disease in which the immune checkpoint molecule LILRB4 is involved, but for example, autoimmune disease, cancer, inflammatory disease, allergic disease and the like. Can be mentioned.
- Autoimmune diseases include, for example, Graves' disease, rheumatoid arthritis, Hashimoto thyroiditis, type 1 diabetes, systemic lupus erythematosus, vasculitis, Addison's disease, polymyositis, dermatomyositis, psoriasis, Sjogren's syndrome, systemic lupus, Examples include glomerulonephritis.
- cancer include lung cancer, colon cancer, renal cancer, malignant melanoma, Hodgkin lymphoma, head and neck cancer, pancreatic cancer, liver cancer, prostate cancer, osteosarcoma, leukemia and the like.
- the cancer may be primary or metastatic, but is preferably used for metastatic cancer.
- Inflammatory diseases include, for example, systemic erythematosus, dermatomyositis, Kawasaki disease, psoriasis, herpes zoster, chronic obstructive pulmonary disease (COPD), bronchial asthma, atopic dermatitis, rheumatoid arthritis, antiphospholipid antibody syndrome, and multiple occurrences.
- COPD chronic obstructive pulmonary disease
- Dermatomyositis vasculitis syndrome, Schegren's syndrome, Bechet's disease, Basedou's disease, Hashimoto's disease, myocarditis, aortitis syndrome, ulcerative colitis, Crohn's disease, primary biliary cirrhosis, autoimmune hepatitis, autoimmune pancreatitis, Examples thereof include polysclerosis, severe myasthenia, Gillan Valley syndrome, glomerulonephritis, ANCA-related nephritis, amyloidosis, TINU syndrome, irritable pneumonia, eosinophilia pneumonia, and sarcoidosis.
- Allergic diseases include allergic rhinitis, bronchial asthma, urticaria / atopic dermatitis, herpes zoster, chronic obstructive pulmonary disease (COPD), allergic conjunctivitis, food allergy, anaphylaxis, autoimmune hematopoietic anemia, and thrombocytopenia.
- COPD chronic obstructive pulmonary disease
- Granulocytopenia a progressive hemorrhagic jaundice
- serum disease irritable pneumonia
- lupus nephritis chronic glomerulonephritis
- systemic lupus erythematosus contact dermatitis
- Hashimoto disease Hashimoto disease
- Bechet's disease rejection after organ transplantation and grafts Anti-host disease (GVHD) and the like
- GVHD Anti-host disease
- the therapeutic agent for immune checkpoint-related diseases of the present invention may contain a substance that activates LILRB4 as an active ingredient.
- the substance that activates LILRB4 is not particularly limited as long as it is a substance that activates LILRB4 by binding to LILRB4, but for example, an anti-fibronectin antibody or a derivative thereof, an anti-fibronectin antibody or a derivative thereof, fibronectin or Examples thereof include fibronectin analogs.
- Examples of the anti-fibronectin antibody or derivative thereof, anti-LILRB4 antibody or derivative thereof, fibronectin or fibronectin analog include those described above, and the immune checkpoint-related diseases containing a substance that activates LILRB4 of the present invention as an active ingredient.
- the anti-fibronectin antibody or derivative thereof, the anti-LILRB4 antibody or derivative thereof, fibronectin or fibronectin analog activates LILRB4 by binding to LILRB4 and expresses the immunosuppressive function of LILRB4.
- the immune checkpoint-related disease is a disease that has a therapeutic effect by suppressing immune function by activating LILRB4. If this is the case, there is no particular limitation, and examples thereof include bone diseases such as rheumatoid arthritis, marble bone disease, and osteoporosis.
- the substance that activates LILRB4 of the present invention can treat bone diseases, for example, by suppressing the proliferation of osteoclasts.
- the therapeutic agent for immune checkpoint-related diseases of the present invention may further contain a pharmaceutically acceptable carrier or additive.
- Pharmaceutically acceptable carriers and additives include those described above.
- the therapeutic agent for immune checkpoint-related diseases of the present invention can be in various forms such as liquid (for example, injection), dispersant, suspension, tablet, pill, powder, suppository and the like.
- a preferred embodiment is an injection, which is preferably administered parenterally (eg, intravenously, transdermally, intraperitoneally, intramuscularly).
- the dose of the therapeutic agent for immune checkpoint-related diseases of the present invention is, for example, 0.025 to 50 mg / kg, preferably 0.1 to 50 mg / kg, more preferably 0.1 to 25 mg / kg, and further. It can preferably be 0.1 to 10 mg / kg or 0.1 to 3 mg / kg, but is not limited to this.
- the immunosuppressant of the present invention contains a substance that activates LILRB4 as an active ingredient.
- the substance that activates LILRB4 include those mentioned in the therapeutic agents for immune checkpoint-related diseases.
- an anti-fibronectin antibody or a derivative thereof, an anti-fibronectin antibody or a derivative thereof, fibronectin or a fibronectin analog binds to LILRB4 to obtain LILRB4. It activates and expresses the immunosuppressive function of LILRB4.
- the immunosuppressant of the present invention can be applied to transplantation medicine.
- the immunosuppressive agent of the present invention may further contain a pharmaceutically acceptable carrier or additive.
- Pharmaceutically acceptable carriers and additives include those described above.
- the immunosuppressive agent of the present invention can be in various forms, for example, a liquid (for example, an injection), a dispersant, a suspension, a tablet, a pill, a powder, a suppository, or the like.
- a preferred embodiment is an injection, which is preferably administered parenterally (eg, intravenously, transdermally, intraperitoneally, intramuscularly).
- the dose of the immunosuppressive agent of the present invention is, for example, 0.025 to 50 mg / kg, preferably 0.1 to 50 mg / kg, more preferably 0.1 to 25 mg / kg, still more preferably 0.1. It can be up to 10 mg / kg or 0.1 to 3 mg / kg, but is not limited to this.
- the kit for detecting fibronectin or a partial peptide thereof of the present invention contains an anti-fibronectin antibody or a derivative thereof that binds to the amino acid sequence represented by SEQ ID NO: 1 and detects the fibronectin or a partial peptide thereof in a biological sample.
- the biological sample is not particularly limited, and examples thereof include blood, saliva, urine, cerebrospinal fluid, bone marrow fluid, pleural effusion, ascites, joint fluid, tear fluid, aqueous humor, vitreous fluid, and lymph fluid.
- the partial peptide of fibronectin is not particularly limited as long as it binds to an anti-fibronectin antibody or a derivative thereof, but is a partial peptide having a molecular weight of 24 kDa including the amino acid sequence represented by SEQ ID NO: 1. Is preferable.
- the kit of the present invention contains other components necessary for the detection of fibronectin, such as a reaction buffer and a reaction vessel. be able to.
- fibronectin or a partial peptide thereof in a biological sample can be detected.
- an anti-fibronectin antibody or a derivative thereof that binds to the amino acid sequence represented by SEQ ID NO: 1 is included, and fibronectin or a partial peptide thereof is detected in the biological sample. If possible, there is no particular limitation, but it is preferable to measure by an immunological method using the anti-fibronectin antibody or a derivative thereof.
- Immunological methods include, for example, immunostaining (Western blot), enzyme-linked immunosorbent assay (ELISA), sandwich ELISA, immunoprecipitation, immunoturbidimetric method (TIA or LTIA), enzyme immunoassay, chemoluminescence immunoassay, fluorescence. It can be carried out by subjecting it to an immunoassay, a flow cytometry method, or the like and detecting a band or spot or peak that matches the molecular weight of fibronectin or a partial peptide thereof, but is not limited thereto.
- Example 1 Expression of LILRB4 in mouse T cells
- Anti-mouse CD3 antibody (manufactured by BD Bioscience, Clone: 145-2C11, # 553058) and anti-mouse CD28 antibody (BD) on a 48-well plate (manufactured by Thermo, # 150687).
- gp49B is a molecule homologous to human LILRB4 in mice.
- Suspended spleen cells were seeded in antibody-coated wells at a concentration of 1 ⁇ 10 6 cells / 200 ⁇ L / well and cultured at 37 ° C. under 5% carbon dioxide conditions for 0 to 3 days.
- Cells are harvested from wells, suspended in PBS (-) buffer containing 2% bovine fetal serum and 0.05% sodium azide (# S8032, manufactured by Sigma) and labeled with FITC under ice temperature conditions.
- Anti-mouse CD4 antibody (BioLegend, Clone: GK1.5, # 100406), Alexa647-labeled anti-mouse CD8a antibody (BD Biosciences, Clone: 53-6.7, # 557882), PE-labeled anti-mouse gp49A / B Antibodies (BioLegend, Clone: H1.1, # 144904), BV421-labeled anti-mouse PD-1 antibody (BioLegend, Clone: 29F.1A12, # 135218), PerCP-Cy5.5-labeled anti-mouse Tim-3 (BioLegend, Clone: B8.2C12, # 134012), PE-labeled Armenian hamster IgG (BioLegend, Clone: HTK888, # 400908) as an isotype control antibody, BV421-labeled rat IgG2a (BioLegend, Clone: RT) , # 400549), PerCP-Cy5.5 label
- FIG. 1 shows the expression of B4, PD-1, and Tim-3 in mouse naive CD8-positive T cells.
- FIG. 1 shows the expression of B4, PD-1, and Tim-3 in mouse naive CD8-positive T cells.
- PD-1 expression was slightly observed, but B4 and Tim-3 expression were not observed.
- deficiency of B4 did not affect the expression of PD-1 and Tim-3.
- FIG. 2 shows the expression of B4, PD-1, and Tim-3 after stimulation with anti-CD3 antibody / anti-CD28 antibody in mouse CD8-positive T cells.
- the expression of PD-1 on mouse CD8-positive T cells was almost maximized on the first day by activation stimulation with anti-CD3 antibody / anti-CD28 antibody, but B4 and Tim-3.
- the expression increased slightly on the first day and reached a maximum after the second day, suggesting that the expression was regulated differently from that of PD-1.
- activation stimulation with anti-CD3 antibody / anti-CD28 antibody did not affect PD-1 expression, but Tim-3 expression was attenuated.
- FIG. 3 shows the expression of B4, PD-1, and Tim-3 in mouse naive CD4 positive T cells.
- FIG. 3 shows the expression of B4, PD-1, and Tim-3 in mouse naive CD4 positive T cells.
- FIG. 4 shows the expression of B4, PD-1, and Tim-3 after stimulation with anti-CD3 antibody / anti-CD28 antibody in mouse CD4-positive T cells.
- the expression of PD-1 on mouse CD4-positive T cells was almost maximized on the first day by activation stimulation with anti-CD3 antibody / anti-CD28 antibody, but B4 and Tim-3.
- the expression increased slightly on the first day and reached its maximum after the second day, suggesting that the expression was regulated differently from that of PD-1.
- activation stimulation with anti-CD3 antibody / anti-CD28 antibody did not affect the expression of PD-1, but attenuated the expression of Tim-3.
- FIG. 5 shows the expression of B4 and PD-1 in mouse CD8-positive T cells and CD4-positive T cells after stimulation with anti-CD3 antibody / anti-CD28 antibody.
- FIG. 5 shows the expression of B4 and PD-1 in mouse CD8-positive T cells and CD4-positive T cells after stimulation with anti-CD3 antibody / anti-CD28 antibody.
- PD-1 expression increased first, then B4 expression increased later, and PD-1 and B4 2 It was confirmed that the cells became heavily positive cells.
- B4 is an immune checkpoint molecule expressed in mouse T cells and different from PD-1 and Tim-3.
- Example 2 Expression of LILRB4 in human T cells
- Anti-human CD3 antibody (BD Bioscience, Clone: UCHT1, # 555329) and anti-human CD28 antibody (BD Bioscience) on a 48-well plate (Thermo, # 150687). , Clone: CD28.2, # 555725), each containing 100 ⁇ L of PBS (-) buffer at a concentration of 10 ⁇ g / mL, coating the wells for 30 minutes at room temperature, and then 3 times with 500 ⁇ L PBS (-) buffer. The wells were washed.
- Frozen human peripheral blood mononuclear cells (manufactured by CTL) are rapidly thawed in a warm bath at 37 ° C., 10% bovine fetal serum, 50 ⁇ M 2-mercaptoethanol, 1% penicillin (5000 U / ml) / streptomycin ( After suspending in RPMI-1640 medium (Sigma, # R8755) containing a solution of 5000 ⁇ g / mL and 20 U / ml DNase I (Sigma, # D5025) and culturing overnight, the cells were collected and Naive Pan.
- T cells were purified using T cell Isolation Kit, human (manufactured by Miltenyi, # 130-097-095) and suspended in a DNase I-free medium having the above composition. Suspended T cells were seeded in antibody-coated wells at a concentration of 1 ⁇ 10 6 cells / 200 ⁇ L / well and cultured at 37 ° C. under 5% carbon dioxide conditions for 0 to 3 days. The cells were harvested from the wells, suspended in PBS (-) buffer containing 2% bovine fetal serum and 0.05% sodium azide, and under ice temperature conditions, FITC-labeled anti-human CD4 antibody (BioLegend).
- FIG. 6 shows the expression of B4, PD-1, and Tim-3 after stimulation with anti-CD3 antibody / anti-CD28 antibody in human CD8-positive T cells and CD4-positive T cells.
- FIG. 6 shows that in human CD8-positive T cells and CD4-positive T cells, no expression of B4, PD-1, or Tim-3 was observed without stimulation (day 0). However, an increase in B4 expression was observed as in PD-1 and Tim-3 by activation stimulation with anti-CD3 antibody / anti-CD28 antibody. From the above results, it was clarified that B4 is an immune checkpoint molecule expressed in human T cells and different from PD-1 and Tim-3.
- Example 3 Analysis of binding site of fibronectin to LILRB4 Human fibronectin is translated from various mRNA isoforms transcribed from a single gene located at 2q35, and generally contains a signal peptide of 26 residues. It consists of 2240 to 2843 amino acid residues. Fibronectin exists as a soluble dimer in plasma and as a dimer or multimer on the cell surface and extracellular matrix (ECM).
- ECM extracellular matrix
- Dimeric fibronectin is a structure in which two nearly identical 210 kDa to 250 kDa polypeptides are disulfide-bonded near the C-terminus, and each polypeptide is composed of a large number of functional modules, which are composed of fibrin, It has the property of binding to other proteins including collagen, integrins, heparins, syndecans, and fibronectin.
- BLI Bio-layer interferometry
- the reporter cell assay uses mouse T cells expressing the NFAT-GFP reporter gene and DAP12 using a chimeric receptor whose extracellular domain is human LILRB4 and whose transmembrane and intracellular domains are activated pairedo immunoglobulin-like receptor beta.
- the hybridoma cell line was transfected with a retrovirus vector, and the obtained 5 ⁇ 10 4 reporter cells were cultured with a test protein, and the expression of GFP was analyzed by flow cytometry.
- the N-terminal cathepsin D digested fragment 70 kDa of human fibronectin and its trypsin digested fragment, the N-terminal 30 kDa fragment, are binding, and the C-terminal 45 kDa fragment is subjected to reporter cell assay and BLI analysis. There was no binding. The more C-terminal portion of fibronectin, amino acid residues 607 to 1265, 1266 to 1908, 1277 to 2477, did not induce a signal in either the reporter cell assay or the BLI analysis. From this result, it was shown that the B4 binding site in fibronectin is in the N-terminal 30 kDa fragment (FN30).
- Example 4 Preparation of recombinant fibronectin target sequence-Fc fusion protein N-terminal 30 kDa of human fibronectin (corresponding to the 40th glutamine residue to the 282nd glycine residue, manufactured by Sigma, # 9911, hereinafter also referred to as FN30) A recombinant protein (hereinafter, also referred to as FN30-Fc) fused with Fc of mouse IgG2a was prepared by the following procedure.
- FN30 A DNA fragment encoding FN30 was amplified from human mesenchymal stem cell-derived mRNA with the following primers.
- FN30 Forward Primer 5'-ATAGAATTCGCAGTCCCCCGGTGGCTGTCAGT-3'(SEQ ID NO: 2)
- FN30 Reverse Primer 5'-TTAAGTCTTCCGCTCGATGTGGTGTCTGCAC-3'(SEQ ID NO: 3)
- the amplified FN30 DNA fragment was digested with Eco RI and Bgl II and inserted into the respective sites of the pFUSE-mIgG2Ae1-Fc2 vector.
- This vector introduced mutations of L235E, E318A, K320A, and K322A into the Fc moiety to reduce the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDC) inherent in the Fc of IgG2a. It is a thing.
- the obtained plasmid pFUSE-mIgG2Ae1-Fc2 / FN30 was sequenced and confirmed, and then subjected to protein expression.
- FN30-Fc For expression of FN30-Fc, this plasmid was transfected into CHO-K1 cells with Lipofectamine 2000 and stable transfection cell clones were selected with Zeocin (0.8 mg / ml) and then obtained by ultra-dilution method. It was. Recombinant FN30-Fc was purified from cell culture supernatant on a HiTrap Protein G HP column and then dialyzed against PBS (-).
- Example 5 Preparation of anti-fibronectin antibody An N-terminal 30 kDa fragment (FN30; manufactured by Sigma) of fibronectin obtained by treating human plasma-derived fibronectin with cathepsin D and purifying it using heparin binding after trypsin treatment. , # 9911) was used as an antigen to immunize WKY rats, and iliac lymph node cells were fused with myeloma cells in the presence of 50% polyethylene glycol to obtain hybridomas.
- FN30 N-terminal 30 kDa fragment (FN30; manufactured by Sigma) of fibronectin obtained by treating human plasma-derived fibronectin with cathepsin D and purifying it using heparin binding after trypsin treatment. , # 9911) was used as an antigen to immunize WKY rats, and iliac lymph node cells were fused with myeloma cells in the presence of 50% polyethylene glycol to obtain hybridomas.
- FN30 monoclonal antibody Anti-fibronectin monoclonal antibody (hereinafter referred to as FN30 monoclonal antibody) by selection by ELISA using human FN30, FN30-Fc obtained in Example 4, mouse FN (manufactured by Abcam, # ab92784), and synthetic peptide fragment of FN30. 9 clones of hybridomas producing (also referred to as) were obtained. Table 1 shows the clone names, isotypes, binding properties of mouse MSCs, and binding properties of human MSCs of the established 9 types of anti-FN30 monoclonal antibodies. In the table, (-) indicates no binding, (+) indicates weak binding, and (++) indicates strong binding.
- Example 6 Blocking effect of anti-fibronectin antibody Human bone marrow-derived mesenchymal stem cells (PromoCell, # C-12974) are suspended in a mesenchymal stem cell proliferation medium (PromoCell, C-28009) and 1 ⁇ 10 5 cells / 300 [mu] L / well were seeded in 48-well plates, 37 ° C., were cultured under conditions of 5% carbon dioxide. With the mesenchymal stem cells sufficiently attached to the plate after 24 hours of culturing, the medium was aspirated and removed, and the anti-FN30 monoclonal antibody (No. 1 to No. 9) obtained in Example 5 was 20 ⁇ g / mL.
- a mesenchymal stem cell proliferation medium PromoCell, C-28009
- reporter cells (2B4 cells) were seeded at 1 ⁇ 10 5 cells / 200 ⁇ L / well, 37 °C, were cultured for 18 hours under the conditions of 5% carbon dioxide. After collecting the cells from the wells, the cells were suspended in PBS (-) buffer containing 2% fetal bovine serum and 0.05% sodium azide, measured by BD FACSCalibur flow cytometer (manufactured by BD Biosciences), and measured by FlowJo. The data was analyzed by software. The result is shown in FIG.
- the anti-FN30 monoclonal antibody No. When treated with 1 to 5 and 7 to 9, the GFP expression was equivalent to that of the positive control without antibody, whereas the anti-FN30 monoclonal antibody No. When treated with No. 6, the expression of GFP was equivalent to that of the negative control of reporter cells only. It can be said that the 6 antibody is an antibody that inhibits the binding between FN30 and B4.
- the anti-FN30 monoclonal antibody No. 4, No. 5 and No. No. 6 was strongly stained with both mouse MSC and human MSC.
- the 7 antibodies weakly stained mouse MSCs and human MSCs.
- No. The 9 antibodies only weakly stained human MSCs. No. 1, No. 2. No. 3 and No. Eight antibodies did not stain any MSCs.
- Human cancer cell line Daudi (Berkit lymphoma), HL60 (premyelocytic leukemia), HeLa (cervical epithelioma), HepG2 (hepatocellular carcinoma), Saos-2 (osteosarcoma) 2 Suspended in PBS (-) buffer containing% bovine fetal serum and 0.05% sodium azide, anti-FN30 monoclonal antibody (No.
- fibronectin (FN30) on the cell surface in mouse cancer cell lines was found to be weak at B16F10 and strong at 3LL.
- Daudi, HL60, and HeLa had no cell surface expression
- HepG2 and Saos-2 had strong cell surface expression.
- Example 9 Expression of B4 and PD-1 of intratumorally infiltrating lymphocytes
- the left thigh of a wild-type mouse was subcutaneously inoculated with 5 ⁇ 10 5 cells / 100 ⁇ L / animal of B16F10 cells or 3LL cells, and then. When the diameter grows to about 1.5 cm, the mice are euthanized by excessive inhalation of carbon dioxide gas, and the tumor is taken out to remove the tumor and remove the tumor from Tumor Discovery Kit, mouse (Miltenyi, # 130-096-730) and gentleMACS Dissociator (Miltenyi).
- a single cell suspension was prepared using # 130-093-235), and lymphocytes were collected by specific gravity separation by Percoll (manufactured by GE Healthcare, # 17089102).
- the recovered cells were suspended in PBS (-) buffer containing 2% fetal bovine serum and 0.05% sodium azide, and under ice temperature conditions, FITC-labeled anti-mouse CD4 antibody, Alexa647-labeled anti-mouse CD8a antibody, Stained with PE-labeled anti-mouse gp49A / B antibody, BV421-labeled anti-mouse PD-1 antibody, PE-labeled Armenian hamster IgG as isotype control antibody, and BV421-labeled rat IgG2a, measured by BD FACSAria III cell sorter, and data by FlowJo software. Was analyzed. The results are shown in FIGS. 10 and 11.
- FIG. 10 shows the expression of B4 and PD-1 of intratumoral infiltrating lymphocytes (mouse CD8-positive T cells).
- B4 and PD-1 expression was observed in some of the CD8-positive T cells infiltrating the tumor of B16F10, and most of them were B4 and PD-1 double-positive cells. And B4 alone positive cells were also observed. Most of the CD8-positive T cells infiltrating the 3LL tumor were B4 positive, and more than 80% of them were also PD-1 positive.
- FIG. 11 shows the expression of B4 and PD-1 of intratumoral infiltrating lymphocytes (mouse CD4 positive T cells).
- B4 and PD-1 intratumoral infiltrating lymphocytes (mouse CD4 positive T cells).
- FIG. 11 shows the expression of B4 and PD-1 was observed in some of the CD4-positive T cells infiltrating the tumor of B16F10, and B4 and PD-1 double-positive cells and B4 single-positive cells were observed.
- Most of the CD4-positive T cells infiltrating the 3LL tumor were B4 and PD-1 double-positive cells.
- Example 10 Protein detection by anti-fibronectin polyclonal antibody and anti-fibronectin monoclonal antibody of plasma sample (Western blotting) Using healthy male (age: 25-31 years old) blood as a plasma sample, 10.5 ml / person of blood was collected in a Venoject II vacuum blood collection tube (registered trademark), and 2500 rpm ⁇ with a universal cooling centrifuge (KUBOTA S911). Centrifuge for 3 minutes to separate and collect plasma.
- a Venoject II vacuum blood collection tube registered trademark
- KUBOTA S911 universal cooling centrifuge
- the plasma sample is diluted 15-fold with ultrapure water, a reducing agent (1M ⁇ -ME) and a surfactant (4% SDS) are added, and the mixture is heated at 95 ° C. for 5 minutes and then heated to 7.5%. It was run on an acrylamide gel. After electrophoresis, the separated protein was transferred to a polyvinylidene fluoride (PVDF) membrane.
- PVDF polyvinylidene fluoride
- thermoFisher Dyeing was performed using Pierce ECL Western Blotting Substrate manufactured by the same company. ImageQuant LAS 4000mini manufactured by GE Healthcare Japan was used for image analysis. The results are shown in FIG.
- the anti-FN30 monoclonal antibody No. 4, No. A band of 250 kDa was confirmed at 5.
- a band having a molecular weight of about 24 kDa was observed in both the anti-FN polyclonal antibody and the anti-FN30 monoclonal antibody, confirming the presence of a 24 kDa FN fragment in healthy human plasma.
- Example 11 Quantification of fibronectin full-length molecule and fibronectin 24 kDa fragment in healthy human plasma using anti-fibronectin antibody (ELISA method)
- Anti-FN44 kDa antibody manufactured by Origine, Clone: OTI3F9, hereinafter also referred to as anti-FN44 antibody
- 6 and Collagen binding-FN as an antigen
- polyclonal antibody Anti-Fibronectin antibody, product # Albiti Using F3648 hereinafter, also referred to as anti-FN polyclonal antibody
- carbonate buffer NaHCO 3
- the amount of fibronectin bound to the monoclonal antibody was detected using an anti-FN polyclonal antibody (13500-fold dilution) and an anti-rabbit IgG-HRP antibody (250-fold dilution). TBS 0.1% Tween 20 was used for plate cleaning between each operation. After adding the substrate, the absorbance was measured at a wavelength of 450 nm with a microplate reader (BioRad, Model 680) and quantified. Non-linear approximation was performed by 4-parameter logistic regression based on the absorbance of the standard protein, and the concentration was calculated from the absorbance value of the sample. The result is shown in FIG.
- the fibronectin concentration [A ( ⁇ g / ml)] detected by the anti-FN30 monoclonal antibody and the fibronectin concentration [B ( ⁇ g / ml)] detected by the anti-FN44 antibody are considered to be the concentrations shown in FIG.
- both the 24 kDa-deficient fibronectin and the 24 kDa fibronectin are degradation products, and the polyclonal antibody to which the secondary antibody binds has a molecular weight. Considering that it is roughly proportional, the relationship is as follows.
- the results are shown as a boxplot display showing the first, second and third quartiles and the maximum and minimum values (Fig. 14).
- the full-length molecular concentration of fibronectin was 279 ⁇ 131 ⁇ g / ml, which was in agreement with the known FN concentration (300 ⁇ g / ml).
- Anti-FN30 monoclonal antibody No. Using the difference in each concentration using 6 and anti-FN44 antibody, the FN24 kDa concentration in plasma was calculated to be 6.49 ⁇ 7.44 ⁇ g / ml.
- Example 12 Therapeutic effect of FN30 on autoantibody diseases Whether or not inhibition of FN30 inhibits the binding of gp49B to fibronectin and exhibits a therapeutic effect on autoantibody production by pathogenic plasma cells is as follows. I verified it in this way. Intraperitoneal administration of control IgG or FN30-Fc obtained in Example 4 to BXSB / Ya mice was repeated twice at 2-week intervals. The result is shown in FIG.
- the anti-dsDNA IgG serum antibody titer gradually increased in the group of mice administered with control IgG, but the IgG autoantibody level was relatively constant during the observed period in the FN30-Fc administration group. Was kept in. This inhibitory effect was also observed by intraperitoneally administering the anti-gp49B monoclonal antibody H1.1 to BXSB / Ya mice on the same schedule as FN30-Fc administration (FIG. 16).
- Example 13 Involvement of LILRB4 in cancer metastasis
- Lewis lung carcinoma cells LLC
- WT wild-type B6 mice
- gp49B-deficient mice mice
- mouse melanoma cells B16F10 were injected from the tail vein, and after 30 days and 20 days, respectively, the lungs and liver were excised, and H & E staining or the number of tumor nodules on the surface was counted and evaluated.
- the results of LLC injection are shown in FIGS. 17A to 17D, and the results of B16F10 injection are shown in FIGS. 18A, 18B and 19. As shown in FIGS.
- the metastasis of LLC to the lung was reduced in gp49B-deficient mice compared to WT.
- the site of tumor metastasis was found only in the liver of LLC-injected WT mice, and was not observed in the liver of gp49B-deficient mice.
- FIGS. 18A and 18B the number of tumor nodules on the total surface of the lung was significantly reduced in gp49B-deficient mice (Fig. 18A), and metastasis to the liver was also reduced (Fig. 18B).
- mice were transferred injected at 5 ⁇ 10 6 cells / mouse wild-type and gp49B deficient mice bone marrow cells from the tail vein after 1 day.
- the mice were treated with gentamicin for 1 month, and at 4 weeks after transfer, the total blood image was confirmed by a flow cytometer to confirm the replacement state of donor cells.
- FIG. 19 metastasis to lung and liver was lower in mice adopting gp49B-deficient bone marrow cells than in wild-type mice adopted control mice. From these results, it was shown that gp49B is involved in the metastasis of tumor cells.
- Example 14 Cancer metastasis inhibitory effect by LILRB4 inhibition As shown in Example 12, tumor metastasis decreases when gp49B is deficient. Therefore, inhibition of gp49B using the anti-gp49B monoclonal antibody H1.1. We investigated how tumor metastasis is affected by the following.
- B6 mice injected with B16F10 were injected intraperitoneally 6 times with a control isotype IgG antibody, anti-PD-1 monoclonal antibody, anti-gp49B monoclonal antibody, or a combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody.
- a control isotype IgG antibody anti-PD-1 monoclonal antibody
- anti-gp49B monoclonal antibody anti-gp49B monoclonal antibody
- a combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody were evaluated. The results are shown in FIGS. 20A to 20D. As shown in FIGS.
- the anti-gp49B monoclonal antibody-treated group was equivalent to the anti-PD-1 monoclonal antibody-treated group or the group treated with the combination of the anti-gp49B monoclonal antibody and the anti-PD-1 monoclonal antibody.
- the number of metastatic lesions of B16F10 tumor decreased in both lung and liver.
- B6 mice are injected with LLC (LLC-Luc2) expressing luciferase to control isotype IgG antibody, anti-PD-1 monoclonal antibody, anti-gp49B monoclonal antibody, or a combination of anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody.
- the number of metastatic lesions of LLC-Luc2 tumor decreased in both the lung and liver in the anti-gp49B monoclonal antibody-treated group and the anti-PD-1 monoclonal antibody and anti-gp49B monoclonal antibody combined treatment group. 20E to 20G).
- Example 15 Verification of osteoclast differentiation promoting effect by inhibition of LILRB4 1 Bone marrow cells were harvested from wild B6 mice and F (ab') 2 fragments of 10% FCS and 10 ⁇ g / ml control isotype IgG antibody, anti-gp49B monoclonal antibody H1.1, anti-gp49B monoclonal antibody H1.1 or anti. FN30 monoclonal antibody No. Using ⁇ -MEM medium containing 6, the cells were cultured in 48-well plates at 5.0 ⁇ 10 5 cells / well. After 2 hours of culturing, 20 ng / well of M-CSF was added and the cells were further cultured for 48 hours.
- the differentiation induction into osteoclasts was carried out by adding the F (ab') 2 fragment of the anti-gp49B monoclonal antibody H1.1 or the anti-gp49B monoclonal antibody H1.1, respectively.
- F (ab') 2 fragment of the anti-gp49B monoclonal antibody H1.1 or the anti-gp49B monoclonal antibody H1.1 respectively.
- Osteoclast count / total cell count x 100 was 3.5% and 3.4%, which tended to increase slightly as compared with the case of the control isotype IgG antibody (2.7%).
- anti-FN-30 monoclonal antibody No With the addition of 6, the differentiation induction rate became 7.9%, and a remarkable increase was observed.
- the differentiation induction rate from PBMC to osteoclasts was 13.7%, which was disrupted by the addition of anti-LILRB4 antibody as compared with the case of the control isotype antibody (7.6%). Induction of differentiation into osteoclasts was enhanced about 2-fold.
- Example 17 Verification of osteoclast differentiation promoting effect by inhibition of LILRB4 3 Bone marrow cells were collected from wild-type B6 mice and gp49B-deficient mice and cultured in 24-well plates for 2 days using 10% FCS, 20 ng / ml M-CSF, 1.0 ⁇ 10 6 cells / ml ⁇ -MEM medium. did. Then, in order to induce differentiation into osteoclasts, 10% FCS-added ⁇ -MEM containing 20 ng / well and 100 ng / ml RANKL of M-CSF was added, and TRAP staining was performed 5 days later. The result is shown in FIG.
- the rate of induction of differentiation into osteoclasts was increased approximately 3-fold in bone marrow cells derived from gp49B-deficient mice as compared with bone marrow cells derived from wild-type mice.
- Example 18 Verification of osteoclast differentiation promoting effect by LILRB4 inhibition 4 Femurs were isolated from 18-week-old wild-type B6 mice (female) and 18-week-old gp49B-deficient mice (female), and the Kawamoto method (“Non-osteoclast frozen section preparation technique (Kawamoto method 2008) and its). Application ”Tadafumi Kawamoto“ Pathological Technology Vol. 72, No. 2, p.76-83, 2009 ”), frozen sections were prepared, and TRAP staining was performed to detect osteoclasts. The result is shown in FIG.
- immune checkpoint inhibitors therapeutic agents for immune checkpoint-related diseases, immunosuppressants, anti-fibronectin antibodies or derivatives thereof, fibronectin analogs, kits for detecting fibronectin or partial proteins thereof, and fibronectin or A method for detecting the partial protein can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
Abstract
Description
本願は、2019年8月13日に、日本に出願された特願2019-148423号に基づき優先権を主張し、その内容をここに援用する。
本発明は以下の態様を含む。
[1] フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質を有効成分として含有する免疫チェックポイント阻害剤。
[2] 前記フィブロネクチンが、前記フィブロネクチン中の配列番号1で表されるアミノ酸配列を介して、免疫抑制性受容体LILRB4と結合する、[1]に記載の免疫チェックポイント阻害剤。
[3] 前記フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチンアナログである、[1]又は[2]に記載の免疫チェックポイント阻害剤。
[4] 前記抗フィブロネクチン抗体又はその誘導体が、フィブロネクチン中の配列番号1で表されるアミノ酸配列と結合する、[3]に記載の免疫チェックポイント阻害剤。
[5] 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、[3]に記載の免疫チェックポイント阻害剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
[6] フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質を有効成分として含有する免疫チェックポイント関連疾患の治療剤。
[7] 前記フィブロネクチンが、前記フィブロネクチン中の配列番号1で表されるアミノ酸配列を介して、免疫抑制性受容体LILRB4と結合する、[6]に記載の治療剤。
[8] 前記フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチンアナログである、[6]又は[7]に記載の治療剤。
[9] 前記抗フィブロネクチン抗体又はその誘導体が、フィブロネクチン中の配列番号1で表されるアミノ酸配列と結合する、[8]に記載の治療剤。
[10] 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、[8]に記載の治療剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
[11] 前記免疫チェックポイント関連疾患が、自己免疫疾患、がん、炎症性疾患、及びアレルギー性疾患からなる群から選択される、[6]~[10]のいずれか一項に記載の治療剤。
[12] 前記がんが、がん転移によるものである、[11]に記載の治療剤。
[13] 免疫抑制性受容体LILRB4を活性化する物質を有効成分として含有する免疫チェックポイント関連疾患の治療剤。
[14] 前記免疫抑制性受容体LILRB4を活性化する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチン又はフィブロネクチンアナログである、[13]に記載の治療剤。
[15] 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、[14]に記載の治療剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
[16] 前記免疫チェックポイント関連疾患が、骨疾患である、[13]~[15]のいずれか一項に記載の治療剤。
[17] 免疫抑制性受容体LILRB4を活性化する物質を有効成分として含有する免疫抑制剤。
[18] 前記免疫抑制性受容体LILRB4を活性化する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチン又はフィブロネクチンアナログである、[17]に記載の免疫抑制剤。
[19] 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、[18]に記載の免疫抑制剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
[20] 配列番号1で表されるアミノ酸配列に結合する抗フィブロネクチン抗体又はその誘導体。
[21] 以下の(a)~(c)のいずれか一つのペプチドと免疫グロブリンGのFc領域とが融合したフィブロネクチンアナログ。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
[22] [20]に記載の抗フィブロネクチン抗体又はその誘導体を含み、生体試料中に含まれる配列番号1で表されるアミノ酸配列を含むフィブロネクチンまたはその部分タンパク質を検出するためのキット。
[23] [22]に記載のキットを用いる、生体試料中のフィブロネクチン又はその部分タンパク質を検出する方法。
本発明の免疫チェックポイント阻害剤は、フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質を有効成分として含有する。フィブロネクチンは、前記フィブロネクチン中の配列番号1で表されるアミノ酸配列を介して、LILRB4と結合することができる。すなわち、配列番号1で表されるアミノ酸配列は、LILRB4のフィブロネクチン中の標的配列である。
フィブロネクチンとLILRB4との結合を阻害する物質としては、フィブロネクチンとLILRB4との結合を阻害する活性を有する物質であれば特に制限はないが、抗フィブロネクチン抗体又はその誘導体、抗LILRB4抗体又はその誘導体、フィブロネクチンアナログ等が挙げられる。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド
本発明の免疫チェックポイント阻害剤の投与量は、例えば、0.025~50mg/kg、好ましくは0.1~50mg/kgであり、より好ましくは0.1~25mg/kg、さらに好ましくは0.1~10mg/kg又は0.1~3mg/kgとすることができるが、これに限定されない。
本発明の免疫チェックポイント関連疾患の治療剤は、フィブロネクチンとLILRB4との結合を阻害する物質を有効成分として含有する。
フィブロネクチンとLILRB4との結合を阻害する物質としては、フィブロネクチンとLILRB4との結合を阻害する活性を有する物質であれば特に制限はないが、抗フィブロネクチン抗体又はその誘導体、抗LILRB4抗体又はその誘導体、フィブロネクチンアナログ等が挙げられる。抗フィブロネクチン抗体又はその誘導体、抗LILRB4抗体又はその誘導体、及びフィブロネクチンアナログとしては、前記したものが挙げられる。
がんとしては、例えば、肺がん、大腸がん、腎がん、悪性黒色腫、ホジキンリンパ腫、頭頸部がん、膵がん、肝がん、前立腺がん、骨肉腫、白血病等が挙げられる。がんは、原発性であっても、転移性であってもよいが、転移性のがんに対して、好ましく用いられる。
本発明の免疫抑制剤は、LILRB4を活性化する物質を有効成分として含有する。LILRB4を活性化する物質としては、前記免疫チェックポイント関連疾患の治療剤で挙げられたものが挙げられる。本発明のLILRB4を活性化する物質を有効成分として含有する免疫抑制剤においては、抗フィブロネクチン抗体又はその誘導体、抗LILRB4抗体又はその誘導体、フィブロネクチン又はフィブロネクチンアナログは、LILRB4と結合することにより、LILRB4を活性化し、LILRB4の免疫抑制機能を発現させる。本発明の免疫抑制剤は、移植医療への応用が可能である。
本発明のフィブロネクチンまたはその部分ペプチドを検出するためのキットは、配列番号1で表されるアミノ酸配列に結合する抗フィブロネクチン抗体又はその誘導体を含み、生体試料中の前記フィブロネクチンまたはその部分ペプチドを検出することができる。
生体試料としては、特に制限はなく、例えば血液、唾液、尿、髄液、骨髄液、胸水、腹水、関節液、涙液、眼房水、硝子体液、リンパ液等が挙げられる。
生体試料中のフィブロネクチンまたはその部分ペプチドを検出する方法としては、配列番号1で表されるアミノ酸配列に結合する抗フィブロネクチン抗体又はその誘導体を含み、生体試料中のフィブロネクチンまたはその部分ペプチドを検出することができれば特に制限はないが、前記抗フィブロネクチン抗体又はその誘導体を用いた免疫学的方法により測定することが好ましい。免疫学的方法としては、例えば免疫染色(ウエスタンブロット)、酵素結合免疫吸着測定法(ELISA)、サンドイッチELISA、免疫沈降法、免疫比濁法(TIAやLTIA)、エンザイムイムノアッセイ、化学発光イムノアッセイ、蛍光イムノアッセイ、フローサイトメトリー法等に供し、フィブロネクチンまたはその部分ペプチドの分子量と一致するバンド若しくはスポット、又はピークを検出することにより行うことができるが、これらに限定されない。
48ウェルプレート(Thermo社製、#150687)に抗マウスCD3抗体(BD Bioscience社製、Clone:145-2C11、#553058)および抗マウスCD28抗体(BD Bioscience社製、Clone:37.51、#553298)を各々10μg/mL濃度で含むPBS(-)緩衝液を100μL加え室温で30分間、ウェルをコーティングし、その後500μLのPBS(-)緩衝液で3回ウェルを洗浄した。10週齢のメスのgp49B欠損マウスまたは野生型マウスの脾臓から採取した脾臓細胞を溶血処理後に10%ウシ胎仔血清(BioWest社製、#S1530)、50μM 2-メルカプトエタノール(富士フィルム和光社製、#139-06861)、1%ペニシリン(5000U/ml)/ストレプトマイシン(5000μg/mL)溶液(Sigma社製、#P4458)を含むRPMI-1640培地(Sigma社製、#R8758)に懸濁した。なお、gp49Bは、マウスにおける、ヒトLILRB4と相同な分子である。
48ウェルプレート(Thermo社製、#150687)に抗ヒトCD3抗体(BD Bioscience社製、Clone:UCHT1、#555329)および抗ヒトCD28抗体(BD Bioscience社製、Clone:CD28.2、#555725)を各々10μg/mL濃度で含むPBS(-)緩衝液を100μL加え室温で30分間、ウェルをコーティングし、その後500μLのPBS(-)緩衝液で3回ウェルを洗浄した。凍結ヒト末梢血単核球(C.T.L.社製)を37℃の温浴で急速解凍し、10%ウシ胎仔血清、50μM 2-メルカプトエタノール、1%ペニシリン(5000U/ml)/ストレプトマイシン(5000μg/mL)溶液、20U/ml DNase I(Sigma社製、#D5025)を含むRPMI-1640培地(Sigma社製、#R8758)に懸濁して一晩培養した後、細胞を回収してNaive Pan T cell Isolation Kit,human(Miltenyi社製、#130-097-095)を用いてT細胞を精製し、上記組成のDNase I不含の培地に懸濁した。抗体をコーティングしたウェルに、懸濁したT細胞を1×106細胞/200μL/ウェルの濃度で播種し、37℃、5%二酸化炭素の条件下で0~3日間培養した。細胞は、ウェルから回収した後、2%ウシ胎仔血清と0.05%アジ化ナトリウムを含むPBS(-)緩衝液に懸濁し、氷温条件下で、FITC標識抗ヒトCD4抗体(BioLegend社製、Clone:RPA-T4、#300506)、Alexa647標識抗ヒトCD8a抗体(BioLegend社製、Clone:RPA-T8、#301022)、PE標識抗ヒトCD85k(LILRB4)抗体(eBioscience社製、Clone:ZM4.1、#12-5139-42)、BV421標識抗ヒトPD-1抗体(BioLegend社製、Clone:EH12.2H7、#329920)、PerCP-Cy5.5標識抗ヒトTim-3(BioLegend社製、Clone:F38-2E2、#345016)、アイソタイプコントロール抗体としてPE標識マウスIgG1,k(eBioscience社製、Clone:P3.6.2.8.1、#12-4714-42)、BV421標識マウスIgG1(BioLegend社製、Clone:MOPC-21、#400158)、PerCP-Cy5.5標識マウスIgG1(BD Biosciences社製、Clone:MOPC-21、#552834)を用いて染色し、BD FACSAriaIIIセルソーター(BD Biosciences社製)により測定し、FlowJoソフトウェア(BD Biosciences社製)によりデータを解析した。
以上の結果から、B4は、ヒトT細胞に発現し、PD-1やTim-3とは異なる免疫チェックポイント分子であることが明らかとなった。
ヒトフィブロネクチンは2q35に位置する単一の遺伝子から転写される多種のmRNAアイソフォームから翻訳され、一般的には26残基のシグナルペプチドを含めて2240~2483個のアミノ酸残基からなる。フィブロネクチンは血漿中では可溶性の二量体として存在し、細胞表面や細胞外マトリックス(ECM)では二量体あるいは多量体として存在している。二量体のフィブロネクチンは二本のほぼ同一の210kDa~250kDaのポリペプチドがC末端近くで2つのジスルフィド結合した構造であり、各ポリペプチドは多数の機能的モデュールから構成され、これらモデュールはフィブリン、コラーゲン、インテグリン、ヘパリン、シンデカン、およびフィブロネクチンを含む他のタンパク質と結合する性質を有している。
BLI解析はBLItzを用いて次のようにして行った。ヒトHisタグ付きヒトLILRB4をNi-NTAセンサーに固相化し、結合しなかったタンパク質はリン酸緩衝生理食塩水(PBS)で洗い落とした。このセンサーを被験タンパク質に浸した後、PBSに浸して解離させた。曲線回帰とデータ処理はBLItz Proソフトで行った。
ヒトフィブロネクチンのN末端30kDa(40番グルタミン残基~282番グリシン残基に相当、Sigma社製、#9911、以下、FN30とも称する)をマウスIgG2aのFcと融合させた組換えタンパク質(以下、FN30-Fcとも称する)を以下の手順で調製した。
FN30 フォワードプライマー:5’-ATAGAATTCGCAGTCCCCGGTGGCTGTCAGT-3’(配列番号2)
FN30 リバースプライマー:5’-TTAAGATCTTCCGCTCGATGTGGTCTGCAC-3’(配列番号3)
得られたプラスミドpFUSE-mIgG2Ae1-Fc2/FN30を配列解析して確認した後、タンパク質発現に供した。FN30-Fcの発現のため、本プラスミドをLipofectamine 2000を用いてCHO-K1細胞にトランスフェクトし、安定導入細胞クローンを、Zeocin(0.8mg/ml)で選択した後、限外希釈法で得た。組換えFN30-Fcは細胞培養上清からHiTrap Protein G HPカラムで精製した後、PBS(-)に対して透析した。
ヒト血漿由来フィブロネクチンをカテプシンD処理して得られる70kDa断片をトリプシン処理後にヘパリン結合性を利用して精製したフィブロネクチンのN末端側30kDa断片(FN30;Sigma社製、#9911)を抗原としてWKYラットに免疫し、腸骨リンパ節細胞を50%ポリエチレングリコール存在下でミエローマ細胞と融合させハイブリドーマを得た。ヒトFN30、実施例4で得られたFN30-Fc、マウスFN(Abcam社製、#ab92784)、FN30の合成ペプチド断片を用いたELISAで選択することで、抗フィブロネクチンモノクローナル抗体(以下、FN30モノクローナル抗体とも称する)を産生するハイブリドーマを9クローン得た。樹立した9種類の抗FN30モノクローナル抗体のクローン名、アイソタイプ、マウスMSCとの結合性、ヒトMSCとの結合性を表1に示す。表中、(-)は結合性なし、(+)は弱結合性、(++)は強結合性をそれぞれ表す。
ヒト骨髄由来間葉系幹細胞(PromoCell社製、#C-12974)を間葉系幹細胞増殖培地(PromoCell社製、C-28009)に懸濁して1×105細胞/300μL/ウェルで48ウェルプレートに播種し、37℃、5%二酸化炭素の条件下で培養した。培養24時間後の間葉系幹細胞がプレートに十分に張り付いた状態において、培地を吸引して取り除き、実施例5で得られた抗FN30モノクローナル抗体(No.1~No.9)20μg/mLを含むPBS(-)緩衝液300μLを添加して37℃で1時間反応させた。その後、抗FN30モノクローナル抗体を含むPBS(-)緩衝液を吸引して取り除き、0.5%ウシ胎仔血清、50μM 2-メルカプトエタノール、1%ペニシリン(5000U/ml)/ストレプトマイシン(5000μg/mL)溶液を含むRPMI-1640培地500μLで2回ウェルを洗浄し、同じ組成のRPMI-1640培地に懸濁したB4キメラ受容体GFPレポーター細胞(B4-2B4細胞)またはキメラ受容体を発現していないコントロールGFPレポーター細胞(2B4細胞)を1×105細胞/200μL/wellで播種し、37℃、5%二酸化炭素の条件下で18時間培養した。細胞は、ウェルから回収した後、2%ウシ胎仔血清と0.05%アジ化ナトリウムを含むPBS(-)緩衝液に懸濁し、BD FACSCaliburフローサイトメーター(BD Biosciences社製)により測定し、FlowJoソフトウェアによりデータを解析した。その結果を図7に示す。
酵素処理等をせずにシャーレからピペッティングにより回収したマウス骨髄由来間葉系幹細胞(Cyagen社製、#MUBMX-01001)およびヒト骨髄由来間葉系幹細胞を2%ウシ胎仔血清と0.05%アジ化ナトリウムを含むPBS(-)緩衝液に懸濁し、氷温条件下で、実施例5で得られた抗FN30モノクローナル抗体またはPE標識ラットIgG1,k(BD Biosciences社製、Clone:R3-34、#553925)で処理し、洗浄後にPE標識ヤギ抗ラットIgGポリクローナル抗体(BioLegend社製、#405406)で染色し、BD FACSCaliburフローサイトメーターにより測定し、FlowJoソフトウェアによりデータを解析した。その結果を図8に示す。
酵素処理等をせずにシャーレからピペッティングにより回収したマウスがん細胞株のB16F10(メラノーマ)、3LL(ルイス肺がん)、ヒトがん細胞株のDaudi(バーキットリンパ腫)、HL60(前骨髄球性白血病)、HeLa(子宮頸部類上皮腫)、HepG2(肝細胞がん)、Saos-2(骨肉腫)を2%ウシ胎仔血清と0.05%アジ化ナトリウムを含むPBS(-)緩衝液に懸濁し、氷温条件下で抗FN30モノクローナル抗体(No.5)またはPE標識ラットIgG2a,k(BD Biosciences社製、Clone:R35-95、#554689)で処理し、洗浄後にAlexa488標識ヤギ抗ラットIgGポリクローナル抗体(Invitrogen社製、#A-11006)で染色し、BD FACSCaliburフローサイトメーターにより測定し、FlowJoソフトウェアによりデータを解析した。その結果を図9に示す。
野生型マウスの左足大腿部に、5×105細胞/100μL/匹のB16F10細胞または3LL細胞を皮下接種し、その後、直径が1.5cm程度に成長した段階でマウスを炭酸ガスの過剰吸引により安楽死させ、腫瘍を取り出してTumor Dissociation Kit,mouse(Miltenyi社製、#130-096-730)とgentleMACS Dissociator(Miltenyi社製、#130-093-235)を用いて単細胞懸濁液を調製し、Percoll(GE Healthcare社製、#17089102)による比重分離によりリンパ球を回収した。回収した細胞は、2%ウシ胎仔血清と0.05%アジ化ナトリウムを含むPBS(-)緩衝液に懸濁し、氷温条件下で、FITC標識抗マウスCD4抗体、Alexa647標識抗マウスCD8a抗体、PE標識抗マウスgp49A/B抗体、BV421標識抗マウスPD-1抗体、アイソタイプコントロール抗体としてPE標識アルメニアンハムスターIgG、BV421標識ラットIgG2aを用いて染色し、BD FACSAriaIIIセルソーターにより測定し、FlowJoソフトウェアによりデータを解析した。その結果を図10及び図11に示す。
血漿サンプルとして、健常男性(年齢:25~31歳)血液を用い、血液10.5ml/人をベノジェクトII真空採血管(登録商標)に採取し,ユニバーサル冷却遠心機(KUBOTA S911)にて2500rpm×3分間遠心分離し、血漿を分離・回収した。
実施例5で得られた抗FN30モノクローナル抗体No.6およびCollagen binding-FNを抗原とする抗FN44kDa抗体(Origene社製、Clone:OTI3F9、以下、抗FN44抗体とも称する)及びポリクローナル抗体であるAnti-Fibronectin antibody produced in rabbit(Sigma-Aldrich社製、#F3648、以下、抗FNポリクローナル抗体とも称する)を使用し、96ウェルプレート(Greiner Bio-one社製、MICROLON(登録商標))に各モノクローナル抗体を終濃度4μg/mlとなるよう炭酸バッファー(NaHCO3 0.01M)にて希釈し、4℃、12時間静置にてプレートをコーティングした。1%BSA含有PBSにてブロッキング後、スタンダードFNタンパク(R&D社製、Fibronectin ELISA DuoSet)および健常ヒト血漿を加えた。
スタンダードタンパクの吸光度をもとに4パラメーターロジスティック回帰にて非線形近似を行い、サンプルの吸光度値より濃度を算出した。その結果を図13に示す。抗FN30モノクローナル抗体で検出されるフィブロネクチン濃度[A(μg/ml)]と抗FN44抗体で検出されるフィブロネクチン濃度[B(μg/ml)]は図13に示した濃度と考えられる。
FN30の阻害がgp49Bとフィブロネクチンとの結合を阻害して病原性のプラズマセルによる自己抗体産生に対して治療的な効果を示すかどうかを以下のようにして検証した。
BXSB/YaaマウスにコントロールIgGまたは実施例4で得られたFN30-Fcを腹腔内投与することを2週間の間隔で2回繰り返した。その結果を図15に示す。
この抑制効果はBXSB/Yaaマウスに、FN30-Fc投与と同様のスケジュールで抗gp49Bモノクローナル抗体H1.1を腹腔内に投与することでも同様に観察された(図16)。自己抗体価の上昇抑制は脾臓重量、総脾臓細胞数、総骨髄細胞数、脾臓と骨髄中のプラズマセルの割合、脾臓中のdsDNA自己抗体産生細胞の頻度などに特段の影響を与えていなかった。
LILRB4(マウスではgp49B)が腫瘍の転移に関与するかどうかを評価するため、野生型(WT)B6マウスおよびgp49B欠損マウスにLewis lung carcinoma細胞(LLC)又はマウスメラノーマ細胞B16F10を尾静脈から注入し、それぞれ30日、20日経過後、肺と肝臓を摘出し、H&E染色または表面の腫瘍結節数をカウントして評価した。LLC注入の結果を図17A~図17Dに、B16F10注入の結果を図18A、図18B及び図19示す。
図17A及び図17Bに示したように、LLCの肺への転移はWTに比べ、gp49B欠損マウスで低下した。また、図17C及び図17Dに示したように、腫瘍が転移した部位はLLCを注入されたWTマウスの肝臓のみに見られ、gp49B欠損マウスの肝臓では観察されなかった。
実施例12で示したように、gp49Bを欠損すると腫瘍の転移が減少することから、抗gp49Bモノクローナル抗体H1.1を使ってgp49Bを阻害することで腫瘍の転移がどのように影響を受けるかを以下のようにして調べた。
図20A~図20Dに示したように、抗gp49Bモノクローナル抗体処理群は、抗PD-1モノクローナル抗体処理群、あるいは抗gp49Bモノクローナル抗体と抗PD-1モノクローナル抗体の組み合わせで処理した群と同等に、肺、肝臓ともB16F10腫瘍の転移巣数が低下した。さらに、B6マウスにルシフェラーゼ発現するLLC(LLC-Luc2)を注射して、対照アイソタイプIgG抗体、抗PD-1モノクローナル抗体、抗gp49Bモノクローナル抗体、あるいは抗PD-1モノクローナル抗体と抗gp49Bモノクローナル抗体の組み合わせの効果を調べたところ、抗gp49Bモノクローナル抗体処理群、及び抗PD-1モノクローナル抗体と抗gp49Bモノクローナル抗体の組み合わせ処理群において、肺、肝臓ともLLC-Luc2腫瘍の転移巣数が減少していた(図20E~図20G)。
野生型B6マウスから骨髄細胞を採取し、10%FCS及び10μg/mlの、対照アイソタイプIgG抗体、抗gp49Bモノクローナル抗体H1.1、抗gp49Bモノクローナル抗体H1.1のF(ab’)2フラグメント又は抗FN30モノクローナル抗体No.6を含むα-MEM培地を用い、48ウェルプレートで5.0×105cells/wellで培養した。培養2時間後にM-CSFを20ng/well添加してさらに48時間培養した。この時点からさらに、破骨細胞への分化誘導のために20ng/ml M-CSF及び100ng/ml RANKLを含む10%FCS添加α-MEMを添加し、6日後にTRAP染色を行なった。その結果を、図22に示す。
健常人から採取した血液サンプルから調製した末梢血単核細胞(PBMC)からマグネティックセルソーターMACS(Miltenyi Biotec社製)を用いてCD11b陽性の単球を得た。これを100ng/ml RANKL、25ng/ml M-CSFを含む10%FCS添加α-MED培地中で抗LILRB4モノクローナル抗体ZM4.1(Thermo Fisher Scientific社製)1.0 μg/ml又は対照アイソタイプ抗体としてマウスIgG1κ(Biolegend社製)1.0μg/mlを添加して7日間培養し、TRAP染色した。その結果を図23に示す。
野生型B6マウス及びgp49B欠損マウスから骨髄細胞を採取し、10%FCS、20ng/ml M-CSF、1.0×106cells/mlのα-MEM培地を用い、24ウェルプレートで2日間培養した。その後、破骨細胞への分化誘導のため、M-CSFを20ng/well及び100ng/ml RANKLを含む10%FCS添加α-MEMを添加し、5日後にTRAP染色を行なった。その結果を図24に示す。
18週齢の野生型B6マウス(雌)および18週齢のgp49B欠損マウス(雌)から大腿骨を単離し、川本法(「非脱灰硬組織凍結切片標本作成技術(川本法2008)とその応用」川本忠文「病理技術 72巻2号p.76-83,2009年」)で包埋したのち凍結切片を作成し、TRAP染色して破骨細胞を検出した。その結果を図25に示す。
Claims (23)
- フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質を有効成分として含有する免疫チェックポイント阻害剤。
- 前記フィブロネクチンが、前記フィブロネクチン中の配列番号1で表されるアミノ酸配列を介して、免疫抑制性受容体LILRB4と結合する、請求項1に記載の免疫チェックポイント阻害剤。
- 前記フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチンアナログである、請求項1又は2に記載の免疫チェックポイント阻害剤。
- 前記抗フィブロネクチン抗体又はその誘導体が、フィブロネクチン中の配列番号1で表されるアミノ酸配列と結合する、請求項3に記載の免疫チェックポイント阻害剤。
- 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、請求項3に記載の免疫チェックポイント阻害剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド - フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質を有効成分として含有する免疫チェックポイント関連疾患の治療剤。
- 前記フィブロネクチンが、前記フィブロネクチン中の配列番号1で表されるアミノ酸配列を介して、免疫抑制性受容体LILRB4と結合する、請求項6に記載の治療剤。
- 前記フィブロネクチンと免疫抑制性受容体LILRB4との結合を阻害する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチンアナログである、請求項6又は7に記載の治療剤。
- 前記抗フィブロネクチン抗体又はその誘導体が、フィブロネクチン中の配列番号1で表されるアミノ酸配列と結合する、請求項8に記載の治療剤。
- 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、請求項8に記載の治療剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド - 前記免疫チェックポイント関連疾患が、自己免疫疾患、がん、炎症性疾患、及びアレルギー性疾患からなる群から選択される、請求項6~10のいずれか一項に記載の治療剤。
- 前記がんが、がん転移によるものである、請求項11に記載の治療剤。
- 免疫抑制性受容体LILRB4を活性化する物質を有効成分として含有する免疫チェックポイント関連疾患の治療剤。
- 前記免疫抑制性受容体LILRB4を活性化する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチン又はフィブロネクチンアナログである、請求項13に記載の治療剤。
- 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、請求項14に記載の治療剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド - 前記免疫チェックポイント関連疾患が、骨疾患である、請求項13~15のいずれか一項に記載の治療剤。
- 免疫抑制性受容体LILRB4を活性化する物質を有効成分として含有する免疫抑制剤。
- 前記免疫抑制性受容体LILRB4を活性化する物質が、抗フィブロネクチン抗体又はその誘導体、抗免疫抑制性受容体LILRB4抗体又はその誘導体、若しくはフィブロネクチン又はフィブロネクチンアナログである、請求項17に記載の免疫抑制剤。
- 前記フィブロネクチンアナログが、以下の(a)~(c)のいずれか一つのペプチドである、請求項18に記載の免疫抑制剤。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド - 配列番号1で表されるアミノ酸配列に結合する抗フィブロネクチン抗体又はその誘導体。
- 以下の(a)~(c)のいずれか一つのペプチドと免疫グロブリンGのFc領域とが融合したフィブロネクチンアナログ。
(a)配列番号1で表されるアミノ酸配列を含むペプチド、
(b)配列番号1で表されるアミノ酸配列において、1~数個のアミノ酸が欠失、挿入、置換若しくは付加されたアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド、
(c)配列番号1で表されるアミノ酸配列において、80%以上の同一性を有するアミノ酸配列を含み、且つ、免疫抑制性受容体LILRB4のフィブロネクチン結合部位に対し結合能を有するペプチド - 請求項20に記載の抗フィブロネクチン抗体又はその誘導体を含み、生体試料中に含まれる配列番号1で表されるアミノ酸配列を含むフィブロネクチンまたはその部分タンパク質を検出するためのキット。
- 請求項22に記載のキットを用いる、生体試料中のフィブロネクチン又はその部分タンパク質を検出する方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080062918.2A CN114531851A (zh) | 2019-08-13 | 2020-08-06 | 免疫检查点抑制剂、免疫检查点相关疾病的治疗剂、免疫抑制剂、抗纤维粘连蛋白抗体或其衍生物、纤维粘连蛋白类似物、用于检测纤维粘连蛋白或其部分蛋白质的试剂盒和检测纤维粘连蛋白或其部分蛋白质的方法 |
CN202311204258.9A CN117487012A (zh) | 2019-08-13 | 2020-08-06 | 用于抑制纤维粘连蛋白与lilrb4的结合的抗lilrb4抗体或其衍生物 |
CA3147182A CA3147182A1 (en) | 2019-08-13 | 2020-08-06 | Novel immune checkpoint inhibitors and uses thereof |
AU2020330795A AU2020330795A1 (en) | 2019-08-13 | 2020-08-06 | Immune checkpoint inhibitor, therapeutic agent for immune checkpoint-related disease, immunosuppressant, anti-fibronectin antibody or derivative thereof, fibronectin analog, kit for detecting fibronectin or partial protein thereof, and method for detecting fibronectin or partial protein thereof |
EP20852963.6A EP4014994A4 (en) | 2019-08-13 | 2020-08-06 | IMMUNE CHECKPOINT INHIBITOR, THERAPEUTIC AGENT FOR IMMUNITY WITH CHECKPOINT-RELATED DISEASE, IMMUNOSUPRESSANT, ANTI-FIBRONECTIN ANTIBODY OR DERIVATIVE THEREOF, FIBRONECTIN ANALOGUE, KIT FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF, AND METHODS FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN D AVON |
BR112022002550A BR112022002550A8 (pt) | 2019-08-13 | 2020-08-06 | Inibidor do ponto de controle imunológico, agente terapêutico para doença do ponto de controle imunológico, imunossupressor, anticorpo para fibronectina ou derivado dela, análogo de fibronectina, kit para detectar fibronectina ou uma proteína parcial dela, e método para detectar fibronectina ou uma proteína parcial dela |
MX2022001756A MX2022001756A (es) | 2019-08-13 | 2020-08-06 | Inhibidor del punto de control inmunitario, agente terapeutico para la enfermedad relacionada con el punto de control inmunitario, inmunosupresor, anticuerpo contra la fibronectina o derivado del mismo, analogo de la fibronectina, kit para detectar la fibronectina o una proteina parcial de la misma, y metodo para detectar la fibronectina o una proteina parcial de la misma. |
JP2021539246A JPWO2021029318A5 (ja) | 2020-08-06 | 免疫チェックポイント阻害剤、フィブロネクチンとlilrb4との結合阻害剤、免疫チェックポイント関連疾患の治療剤 | |
US17/634,424 US20220324950A1 (en) | 2019-08-13 | 2020-08-06 | Immune checkpoint inhibitor, therapeutic agent for immune checkpoint-related disease, immunosuppressant, anti-fibronectin antibody or derivative thereof, fibronectin analog, kit for detecting fibronectin or partial protein thereof, and method for detecting fibronectin or partial protein thereof |
KR1020227007906A KR20220056186A (ko) | 2019-08-13 | 2020-08-06 | 면역 체크포인트 저해제, 면역 체크포인트 관련 질환의 치료제, 면역 억제제, 항피브로넥틴 항체 또는 그 유도체, 피브로넥틴 아날로그, 피브로넥틴 또는 그 부분 단백질을 검출하기 위한 키트, 및 피브로넥틴 또는 그 부분 단백질을 검출하는 방법 |
IL290418A IL290418A (en) | 2019-08-13 | 2022-02-07 | Immune checkpoint inhibitor, therapeutic agent for a disease associated with an immune checkpoint, immunosuppressant, anti-fibronectin antibody or its derivative, fibronectin analog, kit for detecting fibronectin or its partial protein and method for detecting fibronectin or its partial protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-148423 | 2019-08-13 | ||
JP2019148423 | 2019-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021029318A1 true WO2021029318A1 (ja) | 2021-02-18 |
Family
ID=74569350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/030175 WO2021029318A1 (ja) | 2019-08-13 | 2020-08-06 | 免疫チェックポイント阻害剤、免疫チェックポイント関連疾患の治療剤、免疫抑制剤、抗フィブロネクチン抗体又はその誘導体、フィブロネクチンアナログ、フィブロネクチンまたはその部分タンパク質を検出するためのキット、及びフィブロネクチンまたはその部分タンパク質を検出する方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220324950A1 (ja) |
EP (1) | EP4014994A4 (ja) |
KR (1) | KR20220056186A (ja) |
CN (2) | CN114531851A (ja) |
AU (1) | AU2020330795A1 (ja) |
BR (1) | BR112022002550A8 (ja) |
CA (1) | CA3147182A1 (ja) |
IL (1) | IL290418A (ja) |
MX (1) | MX2022001756A (ja) |
WO (1) | WO2021029318A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023002943A1 (ja) | 2021-07-20 | 2023-01-26 | 国立大学法人東北大学 | がん患者の予後を予測するためのバイオマーカー、がん患者の予後を予測するための方法、がん患者における、がん治療薬の効果を予測するための方法、及び、がん患者の予後を予測するためのキット |
US11760802B2 (en) | 2019-12-19 | 2023-09-19 | Ngm Biopharmaceuticals, Inc. | ILT3-binding agents and methods of use thereof |
WO2023233665A1 (ja) * | 2022-06-03 | 2023-12-07 | 国立大学法人東北大学 | 免疫細胞の活性化剤、及び免疫細胞関連炎症疾患の治療剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117362433A (zh) * | 2022-06-30 | 2024-01-09 | 杭州尚健生物技术有限公司 | 分离的抗原结合蛋白及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63219393A (ja) * | 1986-12-26 | 1988-09-13 | Takara Shuzo Co Ltd | 抗ヒト・フイブロネクチンモノクロ−ナル抗体 |
JP2008514621A (ja) * | 2004-09-24 | 2008-05-08 | ビオクセル エッセ ピ ア | 20−シクロアルキル,26,27−アルキル/ハロアルキル−ビタミンd3化合物及びその使用方法 |
US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
WO2018234367A1 (en) * | 2017-06-20 | 2018-12-27 | Institut Curie | SUV39H1 HISTONE METHYLTRANSFERASE INHIBITOR FOR USE IN ANTICANCER POLYTHERAPY |
JP2019148423A (ja) | 2018-02-26 | 2019-09-05 | 株式会社オンダ製作所 | 測定工具用補助具 |
WO2019185792A1 (en) * | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102659538B1 (ko) * | 2014-09-28 | 2024-04-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
JP2018025554A (ja) | 2016-07-29 | 2018-02-15 | 国立大学法人東北大学 | 炎症性疾患のマーカー |
WO2018022881A2 (en) * | 2016-07-29 | 2018-02-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
US20210122819A1 (en) * | 2018-01-18 | 2021-04-29 | Adanate, Inc. | Anti-lilrb antibodies and uses thereof |
-
2020
- 2020-08-06 AU AU2020330795A patent/AU2020330795A1/en active Pending
- 2020-08-06 CN CN202080062918.2A patent/CN114531851A/zh active Pending
- 2020-08-06 KR KR1020227007906A patent/KR20220056186A/ko unknown
- 2020-08-06 CN CN202311204258.9A patent/CN117487012A/zh active Pending
- 2020-08-06 BR BR112022002550A patent/BR112022002550A8/pt unknown
- 2020-08-06 CA CA3147182A patent/CA3147182A1/en active Pending
- 2020-08-06 US US17/634,424 patent/US20220324950A1/en active Pending
- 2020-08-06 EP EP20852963.6A patent/EP4014994A4/en active Pending
- 2020-08-06 MX MX2022001756A patent/MX2022001756A/es unknown
- 2020-08-06 WO PCT/JP2020/030175 patent/WO2021029318A1/ja unknown
-
2022
- 2022-02-07 IL IL290418A patent/IL290418A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63219393A (ja) * | 1986-12-26 | 1988-09-13 | Takara Shuzo Co Ltd | 抗ヒト・フイブロネクチンモノクロ−ナル抗体 |
JP2008514621A (ja) * | 2004-09-24 | 2008-05-08 | ビオクセル エッセ ピ ア | 20−シクロアルキル,26,27−アルキル/ハロアルキル−ビタミンd3化合物及びその使用方法 |
US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
WO2018234367A1 (en) * | 2017-06-20 | 2018-12-27 | Institut Curie | SUV39H1 HISTONE METHYLTRANSFERASE INHIBITOR FOR USE IN ANTICANCER POLYTHERAPY |
JP2019148423A (ja) | 2018-02-26 | 2019-09-05 | 株式会社オンダ製作所 | 測定工具用補助具 |
WO2019185792A1 (en) * | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
Non-Patent Citations (17)
Title |
---|
"Technique for Preparation of Thin Frozen Sections from Undecalcified Hard Tissues", KAWAMOTO'S METHOD, 2008 |
BLOOD, vol. 124, no. 6, 7 August 2014 (2014-08-07), pages 924 - 935 |
BR J CANCER, vol. 101, no. 2, 21 July 2009 (2009-07-21), pages 327 - 334 |
J IMMUNOL, vol. 200, no. 3, 1 February 2018 (2018-02-01), pages 1207 - 1219 |
J RHEUMATOL, vol. 14, no. 5, October 1987 (1987-10-01), pages 1052 - 1054 |
J. IMMUNOL METHODS, vol. 249, 1 March 1992 (1992-03-01), pages 147 - 154 |
MORI : "Analysis of differentiation regulation mechanism of human osteoclast cells by LILRB4", THE JOURNAL OF JAPANESE ORTHOPAEDIC SURGICAL SOCIETY, vol. 81, no. 8, 30 November 2006 (2006-11-30), JP, pages S980, XP009527142, ISSN: 0021-5325 * |
MORI, Y. ET AL.: "Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development", J. IMMUNOL., vol. 181, no. 7, 2008, pages 4742 - 4751, XP002546232 * |
NATURE, vol. 356, 12 March 1992 (1992-03-12), pages 152 - 154 |
NATURE, vol. 562, no. 7728, October 2018 (2018-10-01), pages 605 - 609 |
RHEUMATOL INT, vol. 33, no. 1, January 2013 (2013-01-01), pages 37 - 43 |
RHEUMATOLOGY (OXFORD, vol. 46, no. 7, July 2007 (2007-07-01), pages 1071 - 1075 |
See also references of EP4014994A4 |
SEKIGUCHI, K. ET AL.: "Differences in domain structure between pericellular matrix and plasma fibronectins as revealed by domain-specific antibodies combined with limited proteolysis and S-cyanylation: A preliminary note", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 116, no. 2, 1983, pages 534 - 540, XP024845521, DOI: 10.1016/0006-291X(83)90556-9 * |
TADAFUMI KAWAMOTO, PATHOLOGICAL TECHNOLOGY, vol. 72, no. 2, 2009, pages 76 - 83 |
XU, Z. ET AL.: "ILT3.Fc- CD 166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth", JOURNAL OF IMMUNOLOGY, vol. 200, no. 3, 2018, pages 1207 - 1219, XP055439497 * |
YOSHIAKI NAGAMUNEHIROSHI TERADA: "Monoclonal Antibody", 1996, HIROKAWA SHOTEN CO., LTD |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11760802B2 (en) | 2019-12-19 | 2023-09-19 | Ngm Biopharmaceuticals, Inc. | ILT3-binding agents and methods of use thereof |
WO2023002943A1 (ja) | 2021-07-20 | 2023-01-26 | 国立大学法人東北大学 | がん患者の予後を予測するためのバイオマーカー、がん患者の予後を予測するための方法、がん患者における、がん治療薬の効果を予測するための方法、及び、がん患者の予後を予測するためのキット |
WO2023233665A1 (ja) * | 2022-06-03 | 2023-12-07 | 国立大学法人東北大学 | 免疫細胞の活性化剤、及び免疫細胞関連炎症疾患の治療剤 |
Also Published As
Publication number | Publication date |
---|---|
CA3147182A1 (en) | 2021-02-18 |
JPWO2021029318A1 (ja) | 2021-02-18 |
IL290418A (en) | 2022-04-01 |
CN117487012A (zh) | 2024-02-02 |
BR112022002550A8 (pt) | 2022-12-13 |
EP4014994A1 (en) | 2022-06-22 |
US20220324950A1 (en) | 2022-10-13 |
BR112022002550A2 (pt) | 2022-07-19 |
EP4014994A4 (en) | 2023-08-23 |
KR20220056186A (ko) | 2022-05-04 |
CN114531851A (zh) | 2022-05-24 |
AU2020330795A1 (en) | 2022-03-24 |
MX2022001756A (es) | 2022-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021029318A1 (ja) | 免疫チェックポイント阻害剤、免疫チェックポイント関連疾患の治療剤、免疫抑制剤、抗フィブロネクチン抗体又はその誘導体、フィブロネクチンアナログ、フィブロネクチンまたはその部分タンパク質を検出するためのキット、及びフィブロネクチンまたはその部分タンパク質を検出する方法 | |
JP6557827B2 (ja) | 癌治療用医薬組成物 | |
US9453070B2 (en) | Methods for detecting Th1 cells | |
KR20170000346A (ko) | Cd154 결합 폴리펩타이드 및 그 용도 | |
Kitamura et al. | Cx6Mab-1: A novel anti-mouse CXCR6 monoclonal antibody established by N-terminal peptide immunization | |
US8354106B2 (en) | Antibodies against HMGB1 and fragments thereof | |
Tanaka et al. | Development of an anti-human CCR2 monoclonal antibody (C2Mab-9) by N-terminal peptide immunization | |
CN112851819A (zh) | 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用 | |
AU2006295717B2 (en) | T-cell adhesion molecule and antibody directed against the molecule | |
JP2023510468A (ja) | Cd47を標的とする抗体及びその使用 | |
WO2023194656A1 (en) | Monoclonal pd-l1 antibodies | |
Ferrari | Characterisation of scFv A7 reactivity and development of a novel bispecific antibody for targeted therapies in Rheumatoid Arthritis. | |
MX2008004105A (es) | Molecula de adhesion de celulas t y anticuerpo dirigido contra la molecula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20852963 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021539246 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3147182 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022002550 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227007906 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020852963 Country of ref document: EP Effective date: 20220314 |
|
ENP | Entry into the national phase |
Ref document number: 2020330795 Country of ref document: AU Date of ref document: 20200806 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022002550 Country of ref document: BR Free format text: COM BASE NA PORTARIA 405 DE 21/12/2020, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA POIS O CONTEUDO APRESENTADO NA PETICAO NO 870220011852 NAO POSSUI TODOS OS CAMPOS OBRIGATORIOS INFORMADOS, NAO CONSTANDO O CAMPO 150 / 151 . ALEM DISSO, POSSUI O CAMPO 120 COM DADO DIVERGENTE. DEVERA SER INCLUIDO O CAMPO 140 / 141 UMA VEZ QUE O DEPOSITANTE JA POSSUI O NUMERO DO PEDIDO NO BRASIL |
|
ENP | Entry into the national phase |
Ref document number: 112022002550 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220210 |